ID

DB00218|APRD00281||

名称

Moxifloxacin

描述

Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

cas号

151096-09-2

唯一标识码

U188XYD42P

状态

solid

组

approved,investigational,

指示

For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

药效学

Moxifloxacin is a quinolone/fluoroquinolone antibiotic. Moxifloxacin can be used to treat infections caused by the following bacteria: Aerobic Gram-positive microorganisms: Corynebacterium species, Micrococcus luteus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus warneri, Streptococcus pneumoniae, and Streptococcus viridans group. Aerobic Gram-negative microorganisms: Acinetobacter lwoffii, Haemophilus influenzae, and Haemophilus parainfluenzae. Other microorganisms: Chlamydia trachomatis.
Moxifloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. Moxifloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

作用机制

The bactericidal action of moxifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division.

毒性

Symptoms of overdose include CNS and gastrointestinal effects such as decreased activity, somnolence, tremor, convulsions, vomiting, and diarrhea. The minimal lethal intravenous dose in mice and rats is 100 mg/kg.

代谢

Approximately 52% or oral or intravenous dose is metabolized via glucuronide and sulphate conjugation. The cytochrome P450 system is not involved in metabolism. The sulphate conjugate accounts for 38% of the dose, and the glucuronide conjugate accounts for 14% of the dose.

吸收

Well absorbed from the gastrointestinal tract. Absolute oral bioavailability is approximately 90%. Food has little effect on absorption.

半衰期

11.5-15.6 hours (single dose, oral)

分类

description:This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
direct-parent:Quinoline carboxylic acids
kingdom:Organic compounds
superclass:Organoheterocyclic compounds
class:Quinolines and derivatives
subclass:Quinoline carboxylic acids
alternative-parent:Alkyl aryl ethers
alternative-parent:Amino acids
alternative-parent:Aminoquinolines and derivatives
alternative-parent:Anisoles
alternative-parent:Aryl fluorides
alternative-parent:Azacyclic compounds
alternative-parent:Carboxylic acids
alternative-parent:Dialkylamines
alternative-parent:Dialkylarylamines
alternative-parent:Fluoroquinolones
alternative-parent:Haloquinolines
alternative-parent:Heteroaromatic compounds
alternative-parent:Hydrocarbon derivatives
alternative-parent:Hydroquinolines
alternative-parent:Hydroquinolones
alternative-parent:Methoxyanilines
alternative-parent:Monocarboxylic acids and derivatives
alternative-parent:Organic oxides
alternative-parent:Organofluorides
alternative-parent:Organopnictogen compounds
alternative-parent:Piperidines
alternative-parent:Pyridinecarboxylic acids
alternative-parent:Pyrrolidines
alternative-parent:Pyrrolopyridines
alternative-parent:Vinylogous amides
substituent:Alkyl aryl ether
substituent:Amine
substituent:Amino acid
substituent:Amino acid or derivatives
substituent:Aminoquinoline
substituent:Anisole
substituent:Aromatic heteropolycyclic compound
substituent:Aryl fluoride
substituent:Aryl halide
substituent:Azacycle
substituent:Benzenoid
substituent:Carboxylic acid
substituent:Carboxylic acid derivative
substituent:Dialkylarylamine
substituent:Dihydroquinoline
substituent:Dihydroquinolone
substituent:Ether
substituent:Fluoroquinolone
substituent:Haloquinoline
substituent:Heteroaromatic compound
substituent:Hydrocarbon derivative
substituent:Methoxyaniline
substituent:Monocarboxylic acid or derivatives
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organofluoride
substituent:Organohalogen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Piperidine
substituent:Pyridine
substituent:Pyridine carboxylic acid
substituent:Pyridine carboxylic acid or derivatives
substituent:Pyrrolidine
substituent:Pyrrolopyridine
substituent:Quinoline-3-carboxylic acid
substituent:Secondary aliphatic amine
substituent:Secondary amine
substituent:Tertiary aliphatic/aromatic amine
substituent:Tertiary amine
substituent:Vinylogous amide

消除途径

Approximately 45% of an oral or intravenous dose of moxifloxacin is excreted as unchanged drug (~20% in urine and ~25% in feces).

种类

Anti-Bacterial Agents
D000900
Anti-Infective Agents
D000890
Antibacterials for Systemic Use

Antiinfectives for Systemic Use

Cytochrome P-450 CYP1A2 Inhibitors
D065609
Cytochrome P-450 CYP1A2 Inhibitors (moderate)

Cytochrome P-450 Enzyme Inhibitors
D065607
Enzyme Inhibitors
D004791
Fluoroquinolones
D024841
Heterocyclic Compounds, Fused-Ring
D000072471
Moderate Risk QTc-Prolonging Agents

Ophthalmologicals

QTc Prolonging Agents

Quinolines
D011804
Quinolone Antimicrobial

Quinolones
D015363
Sensory Organs

Topoisomerase II Inhibitors
D059005
Topoisomerase Inhibitors
D059003

盐类

DBSALT000387Moxifloxacin hydrochlorideC53598599T186826-86-8IDIIJJHBXUESQI-DFIJPDEKSA-N437.892437.151762215DBSALT002560Moxifloxacin hydrochloride monohydrateB8956S8609192927-63-2SKZIMSDWAIZNDD-WJMOHVQJSA-N455.91455.1623268

蛋白质结合

50% bound to serum proteins, independent of drug concentration.

清除

* 12 +/- 2 L/hr

同义词

language:english; code:; name;1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
language:english; code:inn; name;Moxifloxacin
language:spanish; code:; name;Moxifloxacino

国际品牌

配送量

* 1.7 to 2.7 L/kg

产品

name:Act Moxifloxacin
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02404656
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-04
ended-marketing-on:
dosage-form:Solution
strength:
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ag-moxifloxacin
labeller:Angita Pharma Inc.
ndc-id:
ndc-product-code:
dpd-id:02478137
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-23
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ag-moxifloxacin
labeller:Angita Pharma Inc.
ndc-id:
ndc-product-code:
dpd-id:02484757
ema-product-code:
ema-ma-number:
started-marketing-on:2020-07-09
ended-marketing-on:
dosage-form:Solution
strength:
route:Ophthalmic
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Apo-moxifloxacin
labeller:Apotex Corporation
ndc-id:
ndc-product-code:
dpd-id:02406373
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-19
ended-marketing-on:
dosage-form:Solution
strength:
route:Ophthalmic
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Apo-moxifloxacin
labeller:Apotex Corporation
ndc-id:
ndc-product-code:
dpd-id:02404923
ema-product-code:
ema-ma-number:
started-marketing-on:2016-01-11
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Auro-moxifloxacin
labeller:Auro Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02432242
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-04
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Avelox
labeller:Red Pharm Drug, Inc.
ndc-id:
ndc-product-code:67296-0154
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-02-25
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avelox
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-4367
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2009-07-16
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avelox
labeller:Remedy Repack
ndc-id:
ndc-product-code:52125-525
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2013-05-24
ended-marketing-on:2017-03-01
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avelox
labeller:Cardinal Health
ndc-id:
ndc-product-code:55154-3516
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2010-03-02
ended-marketing-on:2015-09-30
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avelox
labeller:Bayer HealthCare Pharmaceuticals Inc.
ndc-id:
ndc-product-code:50419-537
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-11-30
ended-marketing-on:2020-06-01
dosage-form:Injection, solution
strength:400 mg/250mL
route:Intravenous
fda-application-number:NDA021277
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avelox
labeller:Bayer HealthCare Pharmaceuticals Inc.
ndc-id:
ndc-product-code:50419-530
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-12-10
ended-marketing-on:2019-06-30
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avelox
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:55289-077
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-12-10
ended-marketing-on:2018-08-01
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avelox
labeller:Schering Plough Corporation
ndc-id:
ndc-product-code:0085-1737
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2001-11-30
ended-marketing-on:2016-07-29
dosage-form:Injection, solution
strength:400 mg/250mL
route:Intravenous
fda-application-number:NDA021277
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avelox
labeller:Schering Plough Corporation
ndc-id:
ndc-product-code:0085-1733
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-12-10
ended-marketing-on:2016-07-29
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avelox
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:49999-455
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-12-07
ended-marketing-on:2017-12-31
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avelox
labeller:Bayer
ndc-id:
ndc-product-code:
dpd-id:02242965
ema-product-code:
ema-ma-number:
started-marketing-on:2000-10-20
ended-marketing-on:2019-07-04
dosage-form:Tablet
strength:400 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Avelox ABC Pack
labeller:Stat Rx USA
ndc-id:
ndc-product-code:16590-881
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:1999-12-10
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Avelox I.V.
labeller:Bayer
ndc-id:
ndc-product-code:
dpd-id:02246414
ema-product-code:
ema-ma-number:
started-marketing-on:2003-06-24
ended-marketing-on:2020-06-29
dosage-form:Solution
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Bio-moxifloxacin
labeller:Biomed Pharma
ndc-id:
ndc-product-code:
dpd-id:02447266
ema-product-code:
ema-ma-number:
started-marketing-on:2016-01-15
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Dex-Moxi
labeller:Imprimis Njof, Llc
ndc-id:
ndc-product-code:71384-512
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-05
ended-marketing-on:
dosage-form:Injection, solution
strength:
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Dex-Moxi PF
labeller:ImprimisRx NJ
ndc-id:
ndc-product-code:70261-512
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-01
ended-marketing-on:
dosage-form:Injection, solution
strength:
route:Intraocular
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Dex-Moxi-Ketor
labeller:Imprimis Njof, Llc
ndc-id:
ndc-product-code:71384-513
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-05
ended-marketing-on:
dosage-form:Injection, solution
strength:
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:DexMoxiKetor PF
labeller:ImprimisRx NJ
ndc-id:
ndc-product-code:70261-513
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-01
ended-marketing-on:
dosage-form:Injection, solution
strength:
route:Intraocular
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Dom-moxifloxacin
labeller:Dominion Pharmacal
ndc-id:
ndc-product-code:
dpd-id:02307154
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Ipg-moxifloxacin
labeller:Marcan Pharmaceuticals Inc
ndc-id:
ndc-product-code:
dpd-id:02446197
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Jamp-moxifloxacin
labeller:Jamp Pharma Corporation
ndc-id:
ndc-product-code:
dpd-id:02443929
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-04
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Jamp-moxifloxacin
labeller:Jamp Pharma Corporation
ndc-id:
ndc-product-code:
dpd-id:02472120
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-28
ended-marketing-on:
dosage-form:Solution
strength:
route:Ophthalmic
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Jamp-moxifloxacin Tablets
labeller:Jamp Pharma Corporation
ndc-id:
ndc-product-code:
dpd-id:02447061
ema-product-code:
ema-ma-number:
started-marketing-on:2016-01-11
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:M-moxifloxacin
labeller:Mantra Pharma Inc
ndc-id:
ndc-product-code:
dpd-id:02472791
ema-product-code:
ema-ma-number:
started-marketing-on:2018-03-07
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Mar-moxifloxacin
labeller:Marcan Pharmaceuticals Inc
ndc-id:
ndc-product-code:
dpd-id:02447053
ema-product-code:
ema-ma-number:
started-marketing-on:2015-12-21
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Med-moxifloxacin
labeller:Generic Medical Partners Inc
ndc-id:
ndc-product-code:
dpd-id:02457814
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Moxeza
labeller:ALCON LABORATORIES, INC.
ndc-id:
ndc-product-code:0065-0006
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2011-01-18
ended-marketing-on:
dosage-form:Solution
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:NDA022428
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Apotex Corp.
ndc-id:
ndc-product-code:60505-0582
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-07-01
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA090080
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Lupin Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68180-422
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-07-01
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA202867
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Fresenius Kabi Norge As
ndc-id:
ndc-product-code:66298-8507
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-08-02
ended-marketing-on:
dosage-form:Injection, solution
strength:400 mg/250mL
route:Intravenous
fda-application-number:NDA205572
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Akorn, Inc.
ndc-id:
ndc-product-code:17478-519
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-11-09
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA202916
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3091
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-07-01
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA090080
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Aidarex Pharmaceuticals LLC
ndc-id:
ndc-product-code:53217-347
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-11-28
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA090080
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Aurobindo Pharma Limited
ndc-id:
ndc-product-code:65862-840
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-10-04
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA206242
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Direct Rx
ndc-id:
ndc-product-code:61919-553
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-30
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA090080
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1679
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-01-01
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA076938
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Fresenius Kabi USA, LLC
ndc-id:
ndc-product-code:63323-850
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-03-18
ended-marketing-on:
dosage-form:Injection, solution
strength:400 mg/250mL
route:Intravenous
fda-application-number:NDA205572
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-3147
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-05
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA076938
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Sunshine Lake Pharma Co., Ltd.
ndc-id:
ndc-product-code:48792-7823
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-10-12
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA206295
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Preferred Pharmaceuticals Inc.
ndc-id:
ndc-product-code:68788-7404
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-11
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA090080
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Dr. Reddy's Laboratories Limited
ndc-id:
ndc-product-code:55111-112
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-05
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA076938
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Major Pharmaceuticals
ndc-id:
ndc-product-code:0904-6406
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-05
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA076938
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Lupin Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:68180-421
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-02-13
ended-marketing-on:
dosage-form:Solution
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA204079
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Direct Rx
ndc-id:
ndc-product-code:72189-076
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-03-04
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA206242
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Mylan Pharmaceuticals Inc.
ndc-id:
ndc-product-code:0378-5430
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-05-28
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA206447
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:55700-657
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-20
ended-marketing-on:2019-10-11
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA202916
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Actavis Pharma, Inc.
ndc-id:
ndc-product-code:0591-3957
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-12-31
ended-marketing-on:2019-12-31
dosage-form:Solution
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA202525
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Lake Erie Medical DBA Quality Care Products LLC
ndc-id:
ndc-product-code:55700-638
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-06-15
ended-marketing-on:2019-10-11
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA076938
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:bryant ranch prepack
ndc-id:
ndc-product-code:63629-8357
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-05
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA076938
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin
labeller:Pro Doc Limitee
ndc-id:
ndc-product-code:
dpd-id:02462974
ema-product-code:
ema-ma-number:
started-marketing-on:2017-04-20
ended-marketing-on:
dosage-form:Tablet
strength:400 mg
route:Oral
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Moxifloxacin Hydrochloride
labeller:Fera Pharmaceuticals
ndc-id:
ndc-product-code:48102-018
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-01-22
ended-marketing-on:2016-01-22
dosage-form:Tablet
strength:400 mg/1
route:Oral
fda-application-number:ANDA205348
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Mylan Pharmaceuticals
ndc-id:
ndc-product-code:0378-2080
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-08-31
ended-marketing-on:2017-03-31
dosage-form:Tablet
strength:400 mg/1
route:Oral
fda-application-number:ANDA204635
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Remedy Repack
ndc-id:
ndc-product-code:61786-360
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-06-26
ended-marketing-on:2016-06-26
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Av Pak
ndc-id:
ndc-product-code:50268-576
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-07-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA202632
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-4100
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-05-02
ended-marketing-on:
dosage-form:Tablet
strength:400 mg/1
route:Oral
fda-application-number:ANDA205348
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:American Health Packaging
ndc-id:
ndc-product-code:68084-722
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-19
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA202632
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Aurobindo Pharma Limited
ndc-id:
ndc-product-code:65862-603
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-04
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA202632
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Mylan Institutional LLC
ndc-id:
ndc-product-code:67457-323
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-10-03
ended-marketing-on:
dosage-form:Injection, solution
strength:400 mg/250mL
route:Intravenous
fda-application-number:ANDA205833
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Rising Health, Llc
ndc-id:
ndc-product-code:57237-156
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-04
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA202632
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Golden State Medical Supply, Inc.
ndc-id:
ndc-product-code:60429-893
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2016-01-14
ended-marketing-on:
dosage-form:Tablet
strength:400 mg/1
route:Oral
fda-application-number:ANDA205348
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:72789-038
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-04
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA202632
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Novel Laboratories, Inc.
ndc-id:
ndc-product-code:40032-034
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-02-13
ended-marketing-on:
dosage-form:Tablet
strength:400 mg/1
route:Oral
fda-application-number:ANDA207285
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1616
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-01
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA202632
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:RedPharm Drug, Inc.
ndc-id:
ndc-product-code:67296-1299
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-29
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:72789-037
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-03-04
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA202632
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Breckenridge Pharmaceutical, Inc.
ndc-id:
ndc-product-code:51991-943
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-05-02
ended-marketing-on:
dosage-form:Tablet
strength:400 mg/1
route:Oral
fda-application-number:ANDA205348
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Torrent Pharmaceuticals Limited
ndc-id:
ndc-product-code:13668-201
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-04-03
ended-marketing-on:
dosage-form:Tablet
strength:400 mg/1
route:Oral
fda-application-number:ANDA200160
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Teva Pharmaceuticals USA, Inc.
ndc-id:
ndc-product-code:0093-7387
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-02-19
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA077437
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Avera McKennan Hospital
ndc-id:
ndc-product-code:69189-0605
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2015-05-22
ended-marketing-on:2017-05-24
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA202632
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-1442
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-29
ended-marketing-on:2017-12-12
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:Alvogen, Inc.
ndc-id:
ndc-product-code:47781-268
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-29
ended-marketing-on:2020-06-01
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:43063-580
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-29
ended-marketing-on:2019-12-05
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:43063-585
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-01-29
ended-marketing-on:2019-12-05
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:NDA021085
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-4058
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-05-02
ended-marketing-on:
dosage-form:Tablet
strength:400 mg/1
route:Oral
fda-application-number:ANDA205348
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride Tablets, 400 mg
labeller:Msn Laboratories Private Limited
ndc-id:
ndc-product-code:69539-006
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2017-09-22
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA208682
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride Tablets, 400 mg
labeller:Novadoz Pharmaceuticals Llc
ndc-id:
ndc-product-code:72205-001
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-21
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA208682
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Hydrochloride Tablets, 400 mg
labeller:PD-Rx Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:72789-080
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-07-21
ended-marketing-on:
dosage-form:Tablet, film coated
strength:400 mg/1
route:Oral
fda-application-number:ANDA208682
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Injection
labeller:Fresenius Kabi
ndc-id:
ndc-product-code:
dpd-id:02433087
ema-product-code:
ema-ma-number:
started-marketing-on:2017-08-16
ended-marketing-on:
dosage-form:Solution
strength:
route:Intravenous
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Moxifloxacin ophthalmic solution
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-4781
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-13
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA209469
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Ophthalmic Solution
labeller:Sandoz Inc
ndc-id:
ndc-product-code:0781-7135
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2003-05-07
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:NDA021598
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Ophthalmic Solution
labeller:Gland Pharma Limited
ndc-id:
ndc-product-code:68083-210
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-03-30
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA208778
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin ophthalmic solution
labeller:Alembic Pharmaceuticals Inc.
ndc-id:
ndc-product-code:62332-505
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-13
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA209469
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin Ophthalmic Solution
labeller:Fosun Pharma USA Inc.
ndc-id:
ndc-product-code:72266-158
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-08-24
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA208778
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin ophthalmic solution
labeller:Rpk Pharmaceuticals, Inc.
ndc-id:
ndc-product-code:53002-2626
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-02-13
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:ANDA209469
generic:true
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Moxifloxacin ophthalmic solution
labeller:Beximco Pharmaceuticals Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02485702
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Solution
strength:0.5 %
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Moxifloxacin PF
labeller:ImprimisRx NJ
ndc-id:
ndc-product-code:70261-511
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-01
ended-marketing-on:
dosage-form:Injection, solution
strength:5 mg/1mL
route:Intraocular
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Moxifloxacin PF
labeller:Imprimis Njof, Llc
ndc-id:
ndc-product-code:71384-509
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2020-02-10
ended-marketing-on:
dosage-form:Injection, solution
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Moxifloxacin PF
labeller:Imprimis Njof, Llc
ndc-id:
ndc-product-code:71384-511
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-05
ended-marketing-on:
dosage-form:Injection, solution
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Mylan-moxifloxacin
labeller:Mylan Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02406136
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Mylan-moxifloxacin HCl Ophthalmic Solution
labeller:Mylan Pharmaceuticals
ndc-id:
ndc-product-code:
dpd-id:02429578
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Solution
strength:
route:Ophthalmic
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:PHL-moxifloxacin
labeller:Pharmel Inc
ndc-id:
ndc-product-code:
dpd-id:02307162
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:PMS-moxifloxacin
labeller:Pharmascience Inc
ndc-id:
ndc-product-code:
dpd-id:02432218
ema-product-code:
ema-ma-number:
started-marketing-on:2015-12-21
ended-marketing-on:
dosage-form:Solution
strength:
route:Ophthalmic
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:PMS-moxifloxacin
labeller:Pharmascience Inc
ndc-id:
ndc-product-code:
dpd-id:02304821
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Priva-moxifloxacin
labeller:Pharmapar Inc
ndc-id:
ndc-product-code:
dpd-id:02447371
ema-product-code:
ema-ma-number:
started-marketing-on:2016-01-15
ended-marketing-on:2019-08-29
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Riva-moxifloxacin
labeller:Laboratoire Riva Inc
ndc-id:
ndc-product-code:
dpd-id:02450976
ema-product-code:
ema-ma-number:
started-marketing-on:2016-03-31
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sandoz Moxifloxacin
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02411520
ema-product-code:
ema-ma-number:
started-marketing-on:2015-10-29
ended-marketing-on:
dosage-form:Solution
strength:
route:Ophthalmic
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Sandoz Moxifloxacin
labeller:Sandoz Canada Incorporated
ndc-id:
ndc-product-code:
dpd-id:02383381
ema-product-code:
ema-ma-number:
started-marketing-on:2017-11-30
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Teva-moxifloxacin
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02375702
ema-product-code:
ema-ma-number:
started-marketing-on:2015-11-04
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Teva-moxifloxacin
labeller:TEVA Canada Limited
ndc-id:
ndc-product-code:
dpd-id:02420511
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Solution
strength:
route:Ophthalmic
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Torrent-moxifloxacin
labeller:Torrent Pharmaceuticals Limited
ndc-id:
ndc-product-code:
dpd-id:02445174
ema-product-code:
ema-ma-number:
started-marketing-on:
ended-marketing-on:
dosage-form:Tablet
strength:
route:Oral
fda-application-number:
generic:true
over-the-counter:false
approved:true
country:Canada
source:DPD
name:Triamcinolone-Moxifloxacin PF
labeller:ImprimisRx NJ
ndc-id:
ndc-product-code:70261-510
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-01
ended-marketing-on:
dosage-form:Suspension
strength:
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Triamcinolone-Moxifloxacin PF
labeller:Imprimis Njof, Llc
ndc-id:
ndc-product-code:71384-510
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2018-01-05
ended-marketing-on:
dosage-form:Injection, suspension
strength:
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:false
country:US
source:FDA NDC
name:Vigamox
labeller:Rebel Distributors
ndc-id:
ndc-product-code:21695-968
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2003-05-07
ended-marketing-on:
dosage-form:Solution
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:NDA021598
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Vigamox
labeller:Physicians Total Care, Inc.
ndc-id:
ndc-product-code:54868-4798
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2003-05-22
ended-marketing-on:
dosage-form:Solution
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:NDA021598
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Vigamox
labeller:A-S Medication Solutions
ndc-id:
ndc-product-code:50090-0859
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2003-05-07
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:NDA021598
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Vigamox
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:70518-2043
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2019-04-26
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:NDA021598
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Vigamox
labeller:ALCON LABORATORIES, INC.
ndc-id:
ndc-product-code:0065-4013
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2003-05-07
ended-marketing-on:
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:NDA021598
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Vigamox
labeller:REMEDYREPACK INC.
ndc-id:
ndc-product-code:61786-058
dpd-id:
ema-product-code:
ema-ma-number:
started-marketing-on:2014-10-09
ended-marketing-on:2018-06-08
dosage-form:Solution / drops
strength:5 mg/1mL
route:Ophthalmic
fda-application-number:NDA021598
generic:false
over-the-counter:false
approved:true
country:US
source:FDA NDC
name:Vigamox
labeller:Novartis
ndc-id:
ndc-product-code:
dpd-id:02252260
ema-product-code:
ema-ma-number:
started-marketing-on:2004-05-12
ended-marketing-on:
dosage-form:Solution
strength:0.5 %
route:Ophthalmic
fda-application-number:
generic:false
over-the-counter:false
approved:true
country:Canada
source:DPD

混合物

name:Avelox ABC Pack
ingredients:Moxifloxacin
name:Avelox
ingredients:Moxifloxacin
name:Avelox
ingredients:Moxifloxacin
name:Vigamox
ingredients:Moxifloxacin
name:Vigamox
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Avelox
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Triamcinolone-Moxifloxacin PF
ingredients:Moxifloxacin + Triamcinolone
name:Avelox
ingredients:Moxifloxacin
name:Dex-Moxi PF
ingredients:Dexamethasone + Moxifloxacin
name:Moxifloxacin PF
ingredients:Moxifloxacin
name:DexMoxiKetor PF
ingredients:Dexamethasone + Ketorolac + Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Vigamox
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride Tablets, 400 mg
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride Tablets, 400 mg
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Avelox
ingredients:Moxifloxacin
name:Avelox
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxeza
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Vigamox
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin ophthalmic solution
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Triamcinolone-Moxifloxacin PF
ingredients:Moxifloxacin + Triamcinolone
name:Dex-Moxi
ingredients:Dexamethasone + Moxifloxacin
name:Dex-Moxi-Ketor
ingredients:Dexamethasone + Ketorolac + Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin Ophthalmic Solution
ingredients:Moxifloxacin
name:Moxifloxacin PF
ingredients:Moxifloxacin
name:Moxifloxacin PF
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride Tablets, 400 mg
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Vigamox
ingredients:Moxifloxacin
name:Moxifloxacin Ophthalmic Solution
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Vigamox
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Avelox
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Avelox
ingredients:Moxifloxacin
name:Avelox
ingredients:Moxifloxacin
name:Avelox
ingredients:Moxifloxacin
name:Moxifloxacin Hydrochloride
ingredients:Moxifloxacin
name:Moxifloxacin ophthalmic solution
ingredients:Moxifloxacin
name:Moxifloxacin Ophthalmic Solution
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin ophthalmic solution
ingredients:Moxifloxacin
name:Avelox
ingredients:Moxifloxacin
name:Avelox I.V.
ingredients:Moxifloxacin
name:Apo-moxifloxacin
ingredients:Moxifloxacin
name:Sandoz Moxifloxacin
ingredients:Moxifloxacin
name:Auro-moxifloxacin
ingredients:Moxifloxacin
name:Teva-moxifloxacin
ingredients:Moxifloxacin
name:Act Moxifloxacin
ingredients:Moxifloxacin
name:PMS-moxifloxacin
ingredients:Moxifloxacin
name:Mar-moxifloxacin
ingredients:Moxifloxacin
name:Teva-moxifloxacin
ingredients:Moxifloxacin
name:Apo-moxifloxacin
ingredients:Moxifloxacin
name:Riva-moxifloxacin
ingredients:Moxifloxacin
name:Jamp-moxifloxacin
ingredients:Moxifloxacin
name:Ipg-moxifloxacin
ingredients:Moxifloxacin
name:PMS-moxifloxacin
ingredients:Moxifloxacin
name:Mylan-moxifloxacin HCl Ophthalmic Solution
ingredients:Moxifloxacin
name:Dom-moxifloxacin
ingredients:Moxifloxacin
name:Mylan-moxifloxacin
ingredients:Moxifloxacin
name:Torrent-moxifloxacin
ingredients:Moxifloxacin
name:Vigamox
ingredients:Moxifloxacin
name:Med-moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin Injection
ingredients:Moxifloxacin
name:PHL-moxifloxacin
ingredients:Moxifloxacin
name:Sandoz Moxifloxacin
ingredients:Moxifloxacin
name:Jamp-moxifloxacin Tablets
ingredients:Moxifloxacin
name:Bio-moxifloxacin
ingredients:Moxifloxacin
name:Priva-moxifloxacin
ingredients:Moxifloxacin
name:M-moxifloxacin
ingredients:Moxifloxacin
name:Jamp-moxifloxacin
ingredients:Moxifloxacin
name:Ag-moxifloxacin
ingredients:Moxifloxacin
name:Ag-moxifloxacin
ingredients:Moxifloxacin
name:Moxifloxacin ophthalmic solution
ingredients:Moxifloxacin

包装者

name:Advanced Pharmaceutical Services Inc.
url:
name:Alcon Laboratories
url:http://www.alcon.com
name:A-S Medication Solutions LLC
url:http://orders.a-smeds.com
name:Bayer Healthcare
url:http://www.bayerhealthcare.com
name:Cardinal Health
url:http://www.cardinal.com
name:Dispensing Solutions
url:http://www.drxdispensing.com
name:Diversified Healthcare Services Inc.
url:http://www.dhscorp.com
name:Fresenius Kabi AB
url:http://www.fresenius-kabi.com
name:H.J. Harkins Co. Inc.
url:http://hjharkinscompanyinc.com
name:Lake Erie Medical and Surgical Supply
url:
name:Murfreesboro Pharmaceutical Nursing Supply
url:http://www.unitdosesupply.com
name:PD-Rx Pharmaceuticals Inc.
url:http://www.pdrx.com
name:Physicians Total Care Inc.
url:http://www.physicianstotalcare.com
name:Prepackage Specialists
url:
name:Redpharm Drug
url:
name:Schering Corp.
url:http://www.schering.de
name:Southwood Pharmaceuticals
url:http://www.southwoodhealthcare.com
name:Stat Rx Usa
url:http://statrxusa.exporterus.com

生产者

generic:否; url:; name;Bayer healthcare pharmaceuticals inc
generic:否; url:; name;Alcon inc
generic:否; url:; name;Bayer Healthcare Pharmaceuticals

价格

Avelox abc pack 400 mg tablet
16.35(单位：USD）
tablet
Avelox 400 mg tablet
16.68(单位：USD）
tablet
Vigamox 0.5% eye drops
27.22(单位：USD）
ml
Vigamox 0.5% Solution 3ml Bottle
90.72(单位：USD）
bottle
Avelox iv 400 mg/250 ml
0.17(单位：USD）
ml

受影响的生物体

Enteric bacteria and other eubacteria

剂量

form:Solution
route:Ophthalmic
strength:
form:Tablet
route:Oral
strength:
form:Injection, solution
route:Parenteral
strength:400 MG/250ML
form:Tablet, film coated
route:Oral
strength:
form:Tablet, film coated
route:Oral
strength:400 MG
form:Injection
route:Intravenous
strength:0.16 %
form:Tablet, film coated
route:Oral
strength:436.8 Mg
form:Tablet, coated
route:Oral
strength:400 mg
form:Injection
route:Intravenous
strength:400 mg
form:Solution
route:Parenteral
strength:400 mg/250ml
form:Tablet, film coated
route:Oral
strength:400 mg/1
form:Solution
route:Intravenous
strength:
form:Solution
route:Intravenous
strength:400 mg/250mL
form:Solution
route:Intravenous
strength:160 mg
form:Solution
route:Ophthalmic
strength:5 mg/ml
form:Solution / drops
route:Ophthalmic
strength:0.5 %
form:Injection, solution
route:Ophthalmic
strength:
form:Injection, solution
route:Intraocular
strength:
form:Solution
route:Intravenous
strength:400 mg
form:Injection
route:Intravenous
strength:400 mg/250ml
form:Solution
route:Conjunctival; Ophthalmic
strength:1 mg
form:Solution / drops
route:Ophthalmic
strength:5.5 mg
form:Solution / drops
route:Ophthalmic
strength:0.5 %w/v
form:Solution / drops
route:Ophthalmic
strength:5 mg/ml
form:Injection, solution
route:Intravenous
strength:400 mg
form:Tablet
route:Oral
strength:400 MG
form:Solution / drops
route:Ophthalmic
strength:5 mg
form:Injection, solution
route:Intravenous
strength:400 mg/250mL
form:Solution / drops
route:Ophthalmic
strength:5 mg/1mL
form:Solution
route:Parenteral
strength:400 mg
form:Injection
route:Intravenous
strength:1.6 mg/ml
form:Solution / drops
route:Ophthalmic
strength:5.5 mg/3ml
form:Tablet, film coated
route:Oral
strength:453.8 MG
form:Injection
route:Intravenous
strength:1.745 mg
form:Tablet
route:Oral
strength:400 mg/1
form:Tablet, film coated
route:Oral
strength:40 MG
form:Tablet, film coated
route:Oral
strength:436.3 MG
form:Solution
route:Intramuscular; Intravenous
strength:400 mg/250ml
form:Injection, solution
route:Intraocular
strength:5 mg/1mL
form:Injection, solution
route:Ophthalmic
strength:5 mg/1mL
form:Injection, solution
route:
strength:400 MG/250ML
form:Solution
route:Ophthalmic
strength:5 mg
form:Injection
route:Intravenous
strength:
form:Solution
route:Ophthalmic
strength:1 mg
form:Solution
route:Conjunctival; Ophthalmic
strength:5 mg
form:Solution
route:Intravenous
strength:1.6 mg
form:Suspension
route:Conjunctival; Ophthalmic
strength:0.1 g
form:Injection, suspension
route:Ophthalmic
strength:
form:Suspension
route:Ophthalmic
strength:
form:Solution / drops
route:Ophthalmic
strength:100 mg/100mL
form:Solution
route:Ophthalmic
strength:5 mg/1mL
form:Solution / drops
route:Ophthalmic
strength:5.45 mg/ml
form:Solution / drops
route:Ophthalmic
strength:500 mg/100mL
form:Solution
route:Ophthalmic
strength:0.5 %
form:Solution / drops
route:Ophthalmic
strength:1.6 g/100mL
form:Solution / drops
route:Ophthalmic
strength:0.5 % W/V

atc代码

Fluoroquinolones
ANTIINFECTIVES
OPHTHALMOLOGICALS
SENSORY ORGANS
Fluoroquinolones
QUINOLONE ANTIBACTERIALS
ANTIBACTERIALS FOR SYSTEMIC USE
ANTIINFECTIVES FOR SYSTEMIC USE

fda标签

//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00218.pdf?1265922809

化学品安全技术说明书

//s3-us-west-2.amazonaws.com/drugbank/msds/DB00218.pdf?1265922746

专利

number:4990517
country:United States
approved:1991-02-05
expires:2011-12-08
pediatric-extension:否
number:2342211
country:Canada
approved:2009-05-26
expires:2019-09-29
pediatric-extension:否
number:1340114
country:Canada
approved:1998-11-03
expires:2015-11-03
pediatric-extension:否
number:5849752
country:United States
approved:1998-12-15
expires:2016-12-05
pediatric-extension:否
number:6610327
country:United States
approved:2003-08-26
expires:2019-10-29
pediatric-extension:否
number:6548079
country:United States
approved:2003-04-15
expires:2020-07-25
pediatric-extension:否
number:7671070
country:United States
approved:2010-03-02
expires:2020-03-29
pediatric-extension:是
number:6716830
country:United States
approved:2004-04-06
expires:2020-03-29
pediatric-extension:是
number:8450311
country:United States
approved:2013-05-28
expires:2029-05-29
pediatric-extension:否
number:9114168
country:United States
approved:2015-08-25
expires:2029-05-29
pediatric-extension:否

食物相互作用

Drink plenty of fluids.Take with or without food.

药物相互作用

DB09083
Ivabradine may increase the QTc-prolonging activities of Moxifloxacin.
DB00900
Didanosine can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01032
Probenecid may decrease the excretion rate of Moxifloxacin which could result in a higher serum level.
DB00881
Quinapril can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00258
Calcium acetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00658
Sevelamer can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00893
Iron Dextran can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01164
Calcium chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01373
Calcium can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06724
Calcium carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06792
Lanthanum carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB08917
Ferric carboxymaltose can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09146
Iron sucrose can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09147
Ferric pyrophosphate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09517
Sodium ferric gluconate complex can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11093
Calcium citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11126
Calcium gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11171
Ferric sulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13949
Ferric cation can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13995
Ferric pyrophosphate citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14520
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14579
Lanthanum III cation can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14684
Calcium polycarbophil can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14695
Ferric oxyhydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00364
Sucralfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00315
The metabolism of Zolmitriptan can be decreased when combined with Moxifloxacin.
DB00698
The therapeutic efficacy of Moxifloxacin can be decreased when used in combination with Nitrofurantoin.
DB06594
The serum concentration of Agomelatine can be increased when it is combined with Moxifloxacin.
DB04951
The serum concentration of Pirfenidone can be increased when it is combined with Moxifloxacin.
DB00697
The serum concentration of Tizanidine can be increased when it is combined with Moxifloxacin.
DB00688
The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Moxifloxacin.
DB01024
The serum concentration of Mycophenolic acid can be decreased when it is combined with Moxifloxacin.
DB09268
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Moxifloxacin.
DB00030
The therapeutic efficacy of Insulin human can be increased when used in combination with Moxifloxacin.
DB00046
The therapeutic efficacy of Insulin lispro can be increased when used in combination with Moxifloxacin.
DB00071
The therapeutic efficacy of Insulin pork can be increased when used in combination with Moxifloxacin.
DB00197
The therapeutic efficacy of Troglitazone can be increased when used in combination with Moxifloxacin.
DB00222
The therapeutic efficacy of Glimepiride can be increased when used in combination with Moxifloxacin.
DB00263
The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Moxifloxacin.
DB00284
The therapeutic efficacy of Acarbose can be increased when used in combination with Moxifloxacin.
DB00331
The therapeutic efficacy of Metformin can be increased when used in combination with Moxifloxacin.
DB00359
The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Moxifloxacin.
DB00412
The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Moxifloxacin.
DB00414
The therapeutic efficacy of Acetohexamide can be increased when used in combination with Moxifloxacin.
DB00491
The therapeutic efficacy of Miglitol can be increased when used in combination with Moxifloxacin.
DB00672
The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Moxifloxacin.
DB00731
The therapeutic efficacy of Nateglinide can be increased when used in combination with Moxifloxacin.
DB00738
The therapeutic efficacy of Pentamidine can be increased when used in combination with Moxifloxacin.
DB00839
The therapeutic efficacy of Tolazamide can be increased when used in combination with Moxifloxacin.
DB00912
The therapeutic efficacy of Repaglinide can be increased when used in combination with Moxifloxacin.
DB00914
The therapeutic efficacy of Phenformin can be increased when used in combination with Moxifloxacin.
DB01015
The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Moxifloxacin.
DB01016
The therapeutic efficacy of Glyburide can be increased when used in combination with Moxifloxacin.
DB01067
The therapeutic efficacy of Glipizide can be increased when used in combination with Moxifloxacin.
DB01120
The therapeutic efficacy of Gliclazide can be increased when used in combination with Moxifloxacin.
DB01124
The therapeutic efficacy of Tolbutamide can be increased when used in combination with Moxifloxacin.
DB01132
The therapeutic efficacy of Pioglitazone can be increased when used in combination with Moxifloxacin.
DB01200
The therapeutic efficacy of Bromocriptine can be increased when used in combination with Moxifloxacin.
DB01251
The therapeutic efficacy of Gliquidone can be increased when used in combination with Moxifloxacin.
DB01252
The therapeutic efficacy of Mitiglinide can be increased when used in combination with Moxifloxacin.
DB01261
The therapeutic efficacy of Sitagliptin can be increased when used in combination with Moxifloxacin.
DB01268
The therapeutic efficacy of Sunitinib can be increased when used in combination with Moxifloxacin.
DB01276
The therapeutic efficacy of Exenatide can be increased when used in combination with Moxifloxacin.
DB01277
The therapeutic efficacy of Mecasermin can be increased when used in combination with Moxifloxacin.
DB01278
The therapeutic efficacy of Pramlintide can be increased when used in combination with Moxifloxacin.
DB01289
The therapeutic efficacy of Glisoxepide can be increased when used in combination with Moxifloxacin.
DB01306
The therapeutic efficacy of Insulin aspart can be increased when used in combination with Moxifloxacin.
DB01309
The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Moxifloxacin.
DB01382
The therapeutic efficacy of Glymidine can be increased when used in combination with Moxifloxacin.
DB01700
The therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Moxifloxacin.
DB04830
The therapeutic efficacy of Buformin can be increased when used in combination with Moxifloxacin.
DB04876
The therapeutic efficacy of Vildagliptin can be increased when used in combination with Moxifloxacin.
DB04878
The therapeutic efficacy of Voglibose can be increased when used in combination with Moxifloxacin.
DB05115
The therapeutic efficacy of NN344 can be increased when used in combination with Moxifloxacin.
DB05819
The therapeutic efficacy of NBI-6024 can be increased when used in combination with Moxifloxacin.
DB06011
The therapeutic efficacy of AMG-222 can be increased when used in combination with Moxifloxacin.
DB06127
The therapeutic efficacy of Bisegliptin can be increased when used in combination with Moxifloxacin.
DB06203
The therapeutic efficacy of Alogliptin can be increased when used in combination with Moxifloxacin.
DB06292
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Moxifloxacin.
DB06335
The therapeutic efficacy of Saxagliptin can be increased when used in combination with Moxifloxacin.
DB06655
The therapeutic efficacy of Liraglutide can be increased when used in combination with Moxifloxacin.
DB08382
The therapeutic efficacy of Gosogliptin can be increased when used in combination with Moxifloxacin.
DB08882
The therapeutic efficacy of Linagliptin can be increased when used in combination with Moxifloxacin.
DB08907
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Moxifloxacin.
DB08962
The therapeutic efficacy of Glibornuride can be increased when used in combination with Moxifloxacin.
DB09022
The therapeutic efficacy of Benfluorex can be increased when used in combination with Moxifloxacin.
DB09038
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Moxifloxacin.
DB09043
The therapeutic efficacy of Albiglutide can be increased when used in combination with Moxifloxacin.
DB09045
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Moxifloxacin.
DB09198
The therapeutic efficacy of Lobeglitazone can be increased when used in combination with Moxifloxacin.
DB09199
The therapeutic efficacy of Netoglitazone can be increased when used in combination with Moxifloxacin.
DB09200
The therapeutic efficacy of Rivoglitazone can be increased when used in combination with Moxifloxacin.
DB09201
The therapeutic efficacy of Ciglitazone can be increased when used in combination with Moxifloxacin.
DB09265
The therapeutic efficacy of Lixisenatide can be increased when used in combination with Moxifloxacin.
DB09456
The therapeutic efficacy of Insulin beef can be increased when used in combination with Moxifloxacin.
DB09564
The therapeutic efficacy of Insulin degludec can be increased when used in combination with Moxifloxacin.
DB11567
The therapeutic efficacy of Insulin peglispro can be increased when used in combination with Moxifloxacin.
DB11568
The therapeutic efficacy of Insulin tregopil can be increased when used in combination with Moxifloxacin.
DB11698
The therapeutic efficacy of Ipragliflozin can be increased when used in combination with Moxifloxacin.
DB11723
The therapeutic efficacy of Dutogliptin can be increased when used in combination with Moxifloxacin.
DB11780
The therapeutic efficacy of Allicin can be increased when used in combination with Moxifloxacin.
DB11824
The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Moxifloxacin.
DB11827
The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Moxifloxacin.
DB11898
The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Moxifloxacin.
DB11950
The therapeutic efficacy of Teneligliptin can be increased when used in combination with Moxifloxacin.
DB11992
The therapeutic efficacy of Omarigliptin can be increased when used in combination with Moxifloxacin.
DB12268
The therapeutic efficacy of Carmegliptin can be increased when used in combination with Moxifloxacin.
DB12412
The therapeutic efficacy of Gemigliptin can be increased when used in combination with Moxifloxacin.
DB12417
The therapeutic efficacy of Anagliptin can be increased when used in combination with Moxifloxacin.
DB12625
The therapeutic efficacy of Evogliptin can be increased when used in combination with Moxifloxacin.
DB12713
The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Moxifloxacin.
DB12781
The therapeutic efficacy of Balaglitazone can be increased when used in combination with Moxifloxacin.
DB12935
The therapeutic efficacy of Remogliflozin etabonate can be increased when used in combination with Moxifloxacin.
DB13406
The therapeutic efficacy of Carbutamide can be increased when used in combination with Moxifloxacin.
DB13446
The therapeutic efficacy of Guar gum can be increased when used in combination with Moxifloxacin.
DB13675
The therapeutic efficacy of Metahexamide can be increased when used in combination with Moxifloxacin.
DB13928
The therapeutic efficacy of Semaglutide can be increased when used in combination with Moxifloxacin.
DB14027
The therapeutic efficacy of Taspoglutide can be increased when used in combination with Moxifloxacin.
DB14035
The therapeutic efficacy of Englitazone can be increased when used in combination with Moxifloxacin.
DB15171
The therapeutic efficacy of Tirzepatide can be increased when used in combination with Moxifloxacin.
DB15217
The therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Moxifloxacin.
DB00047
The therapeutic efficacy of Insulin glargine can be increased when used in combination with Moxifloxacin.
DB01307
The therapeutic efficacy of Insulin detemir can be increased when used in combination with Moxifloxacin.
DB00159
Icosapent may increase the neuroexcitatory activities of Moxifloxacin.
DB00244
Mesalazine may increase the neuroexcitatory activities of Moxifloxacin.
DB00328
Indomethacin may increase the neuroexcitatory activities of Moxifloxacin.
DB00465
Ketorolac may increase the neuroexcitatory activities of Moxifloxacin.
DB00469
Tenoxicam may increase the neuroexcitatory activities of Moxifloxacin.
DB00482
Celecoxib may increase the neuroexcitatory activities of Moxifloxacin.
DB00500
Tolmetin may increase the neuroexcitatory activities of Moxifloxacin.
DB00554
Piroxicam may increase the neuroexcitatory activities of Moxifloxacin.
DB00573
Fenoprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB00580
Valdecoxib may increase the neuroexcitatory activities of Moxifloxacin.
DB00605
Sulindac may increase the neuroexcitatory activities of Moxifloxacin.
DB00712
Flurbiprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB00749
Etodolac may increase the neuroexcitatory activities of Moxifloxacin.
DB00784
Mefenamic acid may increase the neuroexcitatory activities of Moxifloxacin.
DB00795
Sulfasalazine may increase the neuroexcitatory activities of Moxifloxacin.
DB00812
Phenylbutazone may increase the neuroexcitatory activities of Moxifloxacin.
DB00814
Meloxicam may increase the neuroexcitatory activities of Moxifloxacin.
DB00821
Carprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB00861
Diflunisal may increase the neuroexcitatory activities of Moxifloxacin.
DB00936
Salicylic acid may increase the neuroexcitatory activities of Moxifloxacin.
DB00939
Meclofenamic acid may increase the neuroexcitatory activities of Moxifloxacin.
DB00945
Acetylsalicylic acid may increase the neuroexcitatory activities of Moxifloxacin.
DB00991
Oxaprozin may increase the neuroexcitatory activities of Moxifloxacin.
DB01009
Ketoprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB01014
Balsalazide may increase the neuroexcitatory activities of Moxifloxacin.
DB01050
Ibuprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB01250
Olsalazine may increase the neuroexcitatory activities of Moxifloxacin.
DB01283
Lumiracoxib may increase the neuroexcitatory activities of Moxifloxacin.
DB01399
Salsalate may increase the neuroexcitatory activities of Moxifloxacin.
DB01401
Choline magnesium trisalicylate may increase the neuroexcitatory activities of Moxifloxacin.
DB01419
Antrafenine may increase the neuroexcitatory activities of Moxifloxacin.
DB01600
Tiaprofenic acid may increase the neuroexcitatory activities of Moxifloxacin.
DB02224
Taxifolin may increase the neuroexcitatory activities of Moxifloxacin.
DB03585
Oxyphenbutazone may increase the neuroexcitatory activities of Moxifloxacin.
DB04725
Licofelone may increase the neuroexcitatory activities of Moxifloxacin.
DB04743
Nimesulide may increase the neuroexcitatory activities of Moxifloxacin.
DB04812
Benoxaprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB04817
Metamizole may increase the neuroexcitatory activities of Moxifloxacin.
DB04828
Zomepirac may increase the neuroexcitatory activities of Moxifloxacin.
DB05095
Cimicoxib may increase the neuroexcitatory activities of Moxifloxacin.
DB06725
Lornoxicam may increase the neuroexcitatory activities of Moxifloxacin.
DB06736
Aceclofenac may increase the neuroexcitatory activities of Moxifloxacin.
DB06737
Zaltoprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB07402
Azapropazone may increase the neuroexcitatory activities of Moxifloxacin.
DB08439
Parecoxib may increase the neuroexcitatory activities of Moxifloxacin.
DB08797
Salicylamide may increase the neuroexcitatory activities of Moxifloxacin.
DB08940
Kebuzone may increase the neuroexcitatory activities of Moxifloxacin.
DB08942
Isoxicam may increase the neuroexcitatory activities of Moxifloxacin.
DB08951
Indoprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB08955
Ibuproxam may increase the neuroexcitatory activities of Moxifloxacin.
DB08976
Floctafenine may increase the neuroexcitatory activities of Moxifloxacin.
DB08981
Fenbufen may increase the neuroexcitatory activities of Moxifloxacin.
DB08984
Etofenamate may increase the neuroexcitatory activities of Moxifloxacin.
DB08991
Epirizole may increase the neuroexcitatory activities of Moxifloxacin.
DB09084
Benzydamine may increase the neuroexcitatory activities of Moxifloxacin.
DB09213
Dexibuprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB09214
Dexketoprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB09215
Droxicam may increase the neuroexcitatory activities of Moxifloxacin.
DB09216
Tolfenamic acid may increase the neuroexcitatory activities of Moxifloxacin.
DB09217
Firocoxib may increase the neuroexcitatory activities of Moxifloxacin.
DB09218
Clonixin may increase the neuroexcitatory activities of Moxifloxacin.
DB09285
Morniflumate may increase the neuroexcitatory activities of Moxifloxacin.
DB09295
Talniflumate may increase the neuroexcitatory activities of Moxifloxacin.
DB11455
Robenacoxib may increase the neuroexcitatory activities of Moxifloxacin.
DB11466
Tepoxalin may increase the neuroexcitatory activities of Moxifloxacin.
DB11518
Flunixin may increase the neuroexcitatory activities of Moxifloxacin.
DB12399
Polmacoxib may increase the neuroexcitatory activities of Moxifloxacin.
DB12445
Nitroaspirin may increase the neuroexcitatory activities of Moxifloxacin.
DB12545
Indobufen may increase the neuroexcitatory activities of Moxifloxacin.
DB12610
Ebselen may increase the neuroexcitatory activities of Moxifloxacin.
DB13001
Tinoridine may increase the neuroexcitatory activities of Moxifloxacin.
DB13167
Alclofenac may increase the neuroexcitatory activities of Moxifloxacin.
DB13217
Fentiazac may increase the neuroexcitatory activities of Moxifloxacin.
DB13232
Suxibuzone may increase the neuroexcitatory activities of Moxifloxacin.
DB13286
Bumadizone may increase the neuroexcitatory activities of Moxifloxacin.
DB13314
Alminoprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB13371
Difenpiramide may increase the neuroexcitatory activities of Moxifloxacin.
DB13407
Nifenazone may increase the neuroexcitatory activities of Moxifloxacin.
DB13432
Lonazolac may increase the neuroexcitatory activities of Moxifloxacin.
DB13481
Tenidap may increase the neuroexcitatory activities of Moxifloxacin.
DB13524
Propyphenazone may increase the neuroexcitatory activities of Moxifloxacin.
DB13527
Proglumetacin may increase the neuroexcitatory activities of Moxifloxacin.
DB13538
Guacetisal may increase the neuroexcitatory activities of Moxifloxacin.
DB13544
Ethenzamide may increase the neuroexcitatory activities of Moxifloxacin.
DB13612
Carbaspirin calcium may increase the neuroexcitatory activities of Moxifloxacin.
DB13629
Mofebutazone may increase the neuroexcitatory activities of Moxifloxacin.
DB13649
Proquazone may increase the neuroexcitatory activities of Moxifloxacin.
DB13657
Benorilate may increase the neuroexcitatory activities of Moxifloxacin.
DB13722
Pirprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB13783
Acemetacin may increase the neuroexcitatory activities of Moxifloxacin.
DB13860
Imidazole salicylate may increase the neuroexcitatory activities of Moxifloxacin.
DB14059
SC-236 may increase the neuroexcitatory activities of Moxifloxacin.
DB14060
NS-398 may increase the neuroexcitatory activities of Moxifloxacin.
DB14938
Flurbiprofen axetil may increase the neuroexcitatory activities of Moxifloxacin.
DB09212
Loxoprofen may increase the neuroexcitatory activities of Moxifloxacin.
DB09267
Strontium ranelate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00682
The therapeutic efficacy of Warfarin can be increased when used in combination with Moxifloxacin.
DB01418
The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Moxifloxacin.
DB00266
The therapeutic efficacy of Dicoumarol can be increased when used in combination with Moxifloxacin.
DB00498
The therapeutic efficacy of Phenindione can be increased when used in combination with Moxifloxacin.
DB00946
The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Moxifloxacin.
DB03410
The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Moxifloxacin.
DB04665
The therapeutic efficacy of Coumarin can be increased when used in combination with Moxifloxacin.
DB08496
The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Moxifloxacin.
DB08794
The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Moxifloxacin.
DB13136
The therapeutic efficacy of Fluindione can be increased when used in combination with Moxifloxacin.
DB13275
The therapeutic efficacy of Clorindione can be increased when used in combination with Moxifloxacin.
DB13347
The therapeutic efficacy of Diphenadione can be increased when used in combination with Moxifloxacin.
DB13451
The therapeutic efficacy of Tioclomarol can be increased when used in combination with Moxifloxacin.
DB14055
The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Moxifloxacin.
DB00180
The risk or severity of tendinopathy can be increased when Flunisolide is combined with Moxifloxacin.
DB00394
The risk or severity of tendinopathy can be increased when Beclomethasone dipropionate is combined with Moxifloxacin.
DB00443
The risk or severity of tendinopathy can be increased when Betamethasone is combined with Moxifloxacin.
DB00588
The risk or severity of tendinopathy can be increased when Fluticasone propionate is combined with Moxifloxacin.
DB00591
The risk or severity of tendinopathy can be increased when Fluocinolone acetonide is combined with Moxifloxacin.
DB00620
The risk or severity of tendinopathy can be increased when Triamcinolone is combined with Moxifloxacin.
DB00635
The risk or severity of tendinopathy can be increased when Prednisone is combined with Moxifloxacin.
DB00687
The risk or severity of tendinopathy can be increased when Fludrocortisone is combined with Moxifloxacin.
DB00741
The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Moxifloxacin.
DB00860
The risk or severity of tendinopathy can be increased when Prednisolone is combined with Moxifloxacin.
DB00959
The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Moxifloxacin.
DB01108
The risk or severity of tendinopathy can be increased when Trilostane is combined with Moxifloxacin.
DB01222
The risk or severity of tendinopathy can be increased when Budesonide is combined with Moxifloxacin.
DB01234
The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Moxifloxacin.
DB01285
The risk or severity of tendinopathy can be increased when Corticotropin is combined with Moxifloxacin.
DB01380
The risk or severity of tendinopathy can be increased when Cortisone acetate is combined with Moxifloxacin.
DB01384
The risk or severity of tendinopathy can be increased when Paramethasone is combined with Moxifloxacin.
DB01410
The risk or severity of tendinopathy can be increased when Ciclesonide is combined with Moxifloxacin.
DB04630
The risk or severity of tendinopathy can be increased when Aldosterone is combined with Moxifloxacin.
DB08906
The risk or severity of tendinopathy can be increased when Fluticasone furoate is combined with Moxifloxacin.
DB08970
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Moxifloxacin.
DB09091
The risk or severity of tendinopathy can be increased when Tixocortol is combined with Moxifloxacin.
DB09378
The risk or severity of tendinopathy can be increased when Fluprednisolone is combined with Moxifloxacin.
DB09383
The risk or severity of tendinopathy can be increased when Meprednisone is combined with Moxifloxacin.
DB11487
The risk or severity of tendinopathy can be increased when Dexamethasone isonicotinate is combined with Moxifloxacin.
DB11529
The risk or severity of tendinopathy can be increased when Melengestrol is combined with Moxifloxacin.
DB11921
The risk or severity of tendinopathy can be increased when Deflazacort is combined with Moxifloxacin.
DB13003
The risk or severity of tendinopathy can be increased when Cortivazol is combined with Moxifloxacin.
DB13208
The risk or severity of tendinopathy can be increased when Prednylidene is combined with Moxifloxacin.
DB13223
The risk or severity of tendinopathy can be increased when Fluocortin is combined with Moxifloxacin.
DB13491
The risk or severity of tendinopathy can be increased when Fluperolone is combined with Moxifloxacin.
DB13843
The risk or severity of tendinopathy can be increased when Cloprednol is combined with Moxifloxacin.
DB13856
The risk or severity of tendinopathy can be increased when Fluclorolone is combined with Moxifloxacin.
DB13867
The risk or severity of tendinopathy can be increased when Fluticasone is combined with Moxifloxacin.
DB14512
The risk or severity of tendinopathy can be increased when Mometasone furoate is combined with Moxifloxacin.
DB14539
The risk or severity of tendinopathy can be increased when Hydrocortisone acetate is combined with Moxifloxacin.
DB14541
The risk or severity of tendinopathy can be increased when Hydrocortisone cypionate is combined with Moxifloxacin.
DB14545
The risk or severity of tendinopathy can be increased when Hydrocortisone succinate is combined with Moxifloxacin.
DB14631
The risk or severity of tendinopathy can be increased when Prednisolone phosphate is combined with Moxifloxacin.
DB14633
The risk or severity of tendinopathy can be increased when Prednisolone hemisuccinate is combined with Moxifloxacin.
DB14644
The risk or severity of tendinopathy can be increased when Methylprednisolone hemisuccinate is combined with Moxifloxacin.
DB14646
The risk or severity of tendinopathy can be increased when Prednisone acetate is combined with Moxifloxacin.
DB14652
The risk or severity of tendinopathy can be increased when Clocortolone acetate is combined with Moxifloxacin.
DB14659
The risk or severity of tendinopathy can be increased when Melengestrol acetate is combined with Moxifloxacin.
DB14669
The risk or severity of tendinopathy can be increased when Betamethasone phosphate is combined with Moxifloxacin.
DB14681
The risk or severity of tendinopathy can be increased when Cortisone is combined with Moxifloxacin.
DB01013
The risk or severity of tendinopathy can be increased when Clobetasol propionate is combined with Moxifloxacin.
DB01047
The risk or severity of tendinopathy can be increased when Fluocinonide is combined with Moxifloxacin.
DB14540
The risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Moxifloxacin.
DB00547
The risk or severity of tendinopathy can be increased when Desoximetasone is combined with Moxifloxacin.
DB00764
The risk or severity of tendinopathy can be increased when Mometasone is combined with Moxifloxacin.
DB08971
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Moxifloxacin.
DB11750
The risk or severity of tendinopathy can be increased when Clobetasol is combined with Moxifloxacin.
DB15566
The risk or severity of tendinopathy can be increased when Prednisolone acetate is combined with Moxifloxacin.
DB09095
The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Moxifloxacin.
DB00653
Magnesium sulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01397
Magnesium salicylate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB08938
Magaldrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09407
Magnesium chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09511
Talc can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11110
Magnesium citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13322
Hydrotalcite can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13359
Magnesium aspartate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13749
Magnesium gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13786
Magnesium orotate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14514
Magnesium levulinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14515
Magnesium lactate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01377
Magnesium oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09104
Magnesium hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09281
Magnesium trisilicate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09481
Magnesium carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13249
Magnesium silicate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13486
Magnesium peroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01593
Zinc can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB02165
Zinc trihydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB04249
Zinc Substituted Heme C can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09221
Polaprezinc can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09321
Zinc oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09322
Zinc sulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11154
Zinc citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11175
Zinc picolinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11248
Zinc gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14479
Acetylcysteine zinc can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14485
Zinc ascorbate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14487
Zinc acetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14493
Zinc glycinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14533
Zinc chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14548
Zinc sulfate, unspecified form can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14532
Zinc cation can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06723
Aluminum hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13280
Aluminium acetoacetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13595
Almasilate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13626
Aluminium glycinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14517
Aluminium phosphate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00325
Nitroprusside can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01592
Iron can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06215
Ferumoxytol can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06783
Prussian blue can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09501
Ferric ammonium citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09507
Ferumoxsil can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09508
Ferumoxides can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11210
Ferrous bisglycinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11417
Gleptoferron can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11576
Ferric oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB12821
Perflubutane can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13257
Ferrous sulfate anhydrous can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13423
Ferric hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13569
Ferrous chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14488
Ferrous gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14489
Ferrous succinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14491
Ferrous fumarate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13381
Sodium feredetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB15598
Ferric maltol can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB12208
Iron isomaltoside 1000 can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00204
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dofetilide.
DB00215
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Citalopram.
DB00261
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Anagrelide.
DB00280
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Disopyramide.
DB00283
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Clemastine.
DB00308
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ibutilide.
DB00313
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Valproic acid.
DB00342
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Terfenadine.
DB00365
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Grepafloxacin.
DB00468
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Quinine.
DB00489
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sotalol.
DB00530
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Erlotinib.
DB00539
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Toremifene.
DB00604
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Cisapride.
DB00619
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Imatinib.
DB00637
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Astemizole.
DB00679
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Thioridazine.
DB00685
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Trovafloxacin.
DB00834
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mifepristone.
DB00875
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Flupentixol.
DB00907
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Cocaine.
DB00908
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Quinidine.
DB01035
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Procainamide.
DB01100
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Pimozide.
DB01118
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Amiodarone.
DB01169
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Arsenic trioxide.
DB01175
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Escitalopram.
DB01184
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Domperidone.
DB01208
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sparfloxacin.
DB01218
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Halofantrine.
DB01244
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Bepridil.
DB01267
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Paliperidone.
DB01356
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lithium cation.
DB01405
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Temafloxacin.
DB01624
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Zuclopenthixol.
DB04844
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Tetrabenazine.
DB04855
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dronedarone.
DB04868
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nilotinib.
DB04946
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Iloperidone.
DB05294
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Vandetanib.
DB06176
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Romidepsin.
DB06216
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Asenapine.
DB06697
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Artemether.
DB06708
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lumefantrine.
DB08881
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Vemurafenib.
DB09039
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Eliglustat.
DB11730
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ribociclib.
DB11978
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Glasdegib.
DB12161
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Deutetrabenazine.
DB13074
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Macimorelin.
DB13725
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Terodiline.
DB00007
The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Moxifloxacin.
DB00014
The risk or severity of QTc prolongation can be increased when Goserelin is combined with Moxifloxacin.
DB00199
The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Moxifloxacin.
DB00207
The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Moxifloxacin.
DB00243
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ranolazine.
DB00333
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Methadone.
DB00343
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Diltiazem.
DB00391
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sulpiride.
DB00393
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nimodipine.
DB00433
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Prochlorperazine.
DB00450
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Droperidol.
DB00526
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Oxaliplatin.
DB00537
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ciprofloxacin.
DB00556
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Perflutren.
DB00572
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Atropine.
DB00608
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Chloroquine.
DB00625
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Efavirenz.
DB00640
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Adenosine.
DB00743
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Gadobenic acid.
DB00748
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Carbinoxamine.
DB00757
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dolasetron.
DB00778
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Roxithromycin.
DB00779
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nalidixic acid.
DB00827
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Cinoxacin.
DB00836
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Loperamide.
DB00889
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Granisetron.
DB00904
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ondansetron.
DB00922
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Levosimendan.
DB00933
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mesoridazine.
DB00967
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Desloratadine.
DB00976
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Telithromycin.
DB00985
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dimenhydrinate.
DB01113
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Papaverine.
DB01114
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Chlorpheniramine.
DB01137
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Levofloxacin.
DB01155
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Gemifloxacin.
DB01165
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ofloxacin.
DB01193
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Acebutolol.
DB01195
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Flecainide.
DB01211
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Clarithromycin.
DB01227
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Levacetylmethadol.
DB01232
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Saquinavir.
DB01388
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mibefradil.
DB01580
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Oxprenolol.
DB01599
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Probucol.
DB01615
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Aceprometazine.
DB02638
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Terlipressin.
DB04825
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Prenylamine.
DB04842
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Fluspirilene.
DB04957
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Azimilide.
DB05223
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Pracinostat.
DB05488
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Technetium Tc-99m ciprofloxacin.
DB06160
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Garenoxacin.
DB06200
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Tedisamil.
DB06334
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Tucidinostat.
DB06402
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Telavancin.
DB06600
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nemonoxacin.
DB06603
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Panobinostat.
DB06712
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nilvadipine.
DB08799
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Antazoline.
DB08865
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Crizotinib.
DB08903
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Bedaquiline.
DB08980
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Fendiline.
DB08992
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Eperisone.
DB09016
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Butriptyline.
DB09063
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ceritinib.
DB09078
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lenvatinib.
DB09224
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Melperone.
DB09231
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Benidipine.
DB09555
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dexchlorpheniramine maleate.
DB11640
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Amifampridine.
DB11830
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mocetinostat.
DB11841
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Entinostat.
DB12141
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Gilteritinib.
DB12174
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with CUDC-101.
DB12286
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Simendan.
DB12376
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ricolinostat.
DB12523
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mizolastine.
DB12565
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Abexinostat.
DB12877
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Oxatomide.
DB13261
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sitafloxacin.
DB13273
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sultopride.
DB13500
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Otilonium.
DB13546
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nizofenone.
DB13652
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Bunaftine.
DB13653
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lorcainide.
DB13679
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dexchlorpheniramine.
DB13791
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Penfluridol.
DB14063
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dexverapamil.
DB14568
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ivosidenib.
DB01224
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Quetiapine.
DB11718
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Encorafenib.
DB01084
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Emedastine.
DB15982
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Berotralstat.
DB00104
The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moxifloxacin.
DB00107
The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moxifloxacin.
DB00187
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Moxifloxacin.
DB00196
The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Moxifloxacin.
DB00220
The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Moxifloxacin.
DB00230
The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Moxifloxacin.
DB00245
The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Moxifloxacin.
DB00270
The risk or severity of QTc prolongation can be increased when Isradipine is combined with Moxifloxacin.
DB00285
The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Moxifloxacin.
DB00289
The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Moxifloxacin.
DB00341
The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Moxifloxacin.
DB00344
The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Moxifloxacin.
DB00346
The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Moxifloxacin.
DB00347
The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Moxifloxacin.
DB00354
The risk or severity of QTc prolongation can be increased when Buclizine is combined with Moxifloxacin.
DB00358
The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Moxifloxacin.
DB00366
The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Moxifloxacin.
DB00373
The risk or severity of QTc prolongation can be increased when Timolol is combined with Moxifloxacin.
DB00374
The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Moxifloxacin.
DB00390
The risk or severity of QTc prolongation can be increased when Digoxin is combined with Moxifloxacin.
DB00405
The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Moxifloxacin.
DB00424
The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Moxifloxacin.
DB00427
The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Moxifloxacin.
DB00434
The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Moxifloxacin.
DB00467
The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Moxifloxacin.
DB00487
The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Moxifloxacin.
DB00503
The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Moxifloxacin.
DB00529
The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Moxifloxacin.
DB00543
The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Moxifloxacin.
DB00555
The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Moxifloxacin.
DB00582
The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Moxifloxacin.
DB00593
The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Moxifloxacin.
DB00613
The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Moxifloxacin.
DB00622
The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Moxifloxacin.
DB00674
The risk or severity of QTc prolongation can be increased when Galantamine is combined with Moxifloxacin.
DB00678
The risk or severity of QTc prolongation can be increased when Losartan is combined with Moxifloxacin.
DB00680
The risk or severity of QTc prolongation can be increased when Moricizine is combined with Moxifloxacin.
DB00691
The risk or severity of QTc prolongation can be increased when Moexipril is combined with Moxifloxacin.
DB00710
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Moxifloxacin.
DB00714
The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Moxifloxacin.
DB00719
The risk or severity of QTc prolongation can be increased when Azatadine is combined with Moxifloxacin.
DB00726
The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Moxifloxacin.
DB00734
The risk or severity of QTc prolongation can be increased when Risperidone is combined with Moxifloxacin.
DB00753
The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Moxifloxacin.
DB00808
The risk or severity of QTc prolongation can be increased when Indapamide is combined with Moxifloxacin.
DB00817
The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Moxifloxacin.
DB00818
The risk or severity of QTc prolongation can be increased when Propofol is combined with Moxifloxacin.
DB00822
The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Moxifloxacin.
DB00825
The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Moxifloxacin.
DB00835
The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Moxifloxacin.
DB00862
The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Moxifloxacin.
DB00864
The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Moxifloxacin.
DB00871
The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Moxifloxacin.
DB00909
The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Moxifloxacin.
DB00915
The risk or severity of QTc prolongation can be increased when Amantadine is combined with Moxifloxacin.
DB00916
The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Moxifloxacin.
DB00920
The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Moxifloxacin.
DB00927
The risk or severity of QTc prolongation can be increased when Famotidine is combined with Moxifloxacin.
DB00938
The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Moxifloxacin.
DB00949
The risk or severity of QTc prolongation can be increased when Felbamate is combined with Moxifloxacin.
DB00983
The risk or severity of QTc prolongation can be increased when Formoterol is combined with Moxifloxacin.
DB00999
The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Moxifloxacin.
DB01001
The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Moxifloxacin.
DB01023
The risk or severity of QTc prolongation can be increased when Felodipine is combined with Moxifloxacin.
DB01026
The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Moxifloxacin.
DB01036
The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Moxifloxacin.
DB01044
The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Moxifloxacin.
DB01054
The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Moxifloxacin.
DB01059
The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Moxifloxacin.
DB01069
The risk or severity of QTc prolongation can be increased when Promethazine is combined with Moxifloxacin.
DB01071
The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Moxifloxacin.
DB01072
The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Moxifloxacin.
DB01074
The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Moxifloxacin.
DB01075
The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Moxifloxacin.
DB01106
The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Moxifloxacin.
DB01158
The risk or severity of QTc prolongation can be increased when Bretylium is combined with Moxifloxacin.
DB01167
The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Moxifloxacin.
DB01173
The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Moxifloxacin.
DB01176
The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Moxifloxacin.
DB01189
The risk or severity of QTc prolongation can be increased when Desflurane is combined with Moxifloxacin.
DB01228
The risk or severity of QTc prolongation can be increased when Encainide is combined with Moxifloxacin.
DB01233
The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Moxifloxacin.
DB01236
The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Moxifloxacin.
DB01238
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Moxifloxacin.
DB01239
The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Moxifloxacin.
DB01246
The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Moxifloxacin.
DB01259
The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Moxifloxacin.
DB01263
The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Moxifloxacin.
DB01274
The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Moxifloxacin.
DB01396
The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Moxifloxacin.
DB01403
The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Moxifloxacin.
DB01426
The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Moxifloxacin.
DB01591
The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Moxifloxacin.
DB01611
The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Moxifloxacin.
DB01620
The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Moxifloxacin.
DB02546
The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Moxifloxacin.
DB04576
The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Moxifloxacin.
DB04695
The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Moxifloxacin.
DB04846
The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Moxifloxacin.
DB04953
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Moxifloxacin.
DB05039
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Moxifloxacin.
DB05246
The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Moxifloxacin.
DB05465
The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Moxifloxacin.
DB06217
The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Moxifloxacin.
DB06282
The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Moxifloxacin.
DB06288
The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Moxifloxacin.
DB06468
The risk or severity of QTc prolongation can be increased when Cariporide is combined with Moxifloxacin.
DB06663
The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Moxifloxacin.
DB06691
The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Moxifloxacin.
DB06699
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Moxifloxacin.
DB06719
The risk or severity of QTc prolongation can be increased when Buserelin is combined with Moxifloxacin.
DB06788
The risk or severity of QTc prolongation can be increased when Histrelin is combined with Moxifloxacin.
DB06825
The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Moxifloxacin.
DB07780
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Moxifloxacin.
DB07841
The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Moxifloxacin.
DB08808
The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Moxifloxacin.
DB08815
The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Moxifloxacin.
DB08864
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Moxifloxacin.
DB08871
The risk or severity of QTc prolongation can be increased when Eribulin is combined with Moxifloxacin.
DB08893
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Moxifloxacin.
DB08912
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Moxifloxacin.
DB08936
The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Moxifloxacin.
DB08952
The risk or severity of QTc prolongation can be increased when Indenolol is combined with Moxifloxacin.
DB08972
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Moxifloxacin.
DB09080
The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Moxifloxacin.
DB09082
The risk or severity of QTc prolongation can be increased when Vilanterol is combined with Moxifloxacin.
DB09089
The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Moxifloxacin.
DB09090
The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Moxifloxacin.
DB09167
The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Moxifloxacin.
DB09229
The risk or severity of QTc prolongation can be increased when Aranidipine is combined with Moxifloxacin.
DB09235
The risk or severity of QTc prolongation can be increased when Efonidipine is combined with Moxifloxacin.
DB09236
The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Moxifloxacin.
DB09239
The risk or severity of QTc prolongation can be increased when Niguldipine is combined with Moxifloxacin.
DB09488
The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Moxifloxacin.
DB11390
The risk or severity of QTc prolongation can be increased when Coumaphos is combined with Moxifloxacin.
DB11397
The risk or severity of QTc prolongation can be increased when Dichlorvos is combined with Moxifloxacin.
DB11408
The risk or severity of QTc prolongation can be increased when Famphur is combined with Moxifloxacin.
DB11412
The risk or severity of QTc prolongation can be increased when Fenthion is combined with Moxifloxacin.
DB11443
The risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Moxifloxacin.
DB11448
The risk or severity of QTc prolongation can be increased when Phosmet is combined with Moxifloxacin.
DB11491
The risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Moxifloxacin.
DB11511
The risk or severity of QTc prolongation can be increased when Difloxacin is combined with Moxifloxacin.
DB11591
The risk or severity of QTc prolongation can be increased when Bilastine is combined with Moxifloxacin.
DB11614
The risk or severity of QTc prolongation can be increased when Rupatadine is combined with Moxifloxacin.
DB11742
The risk or severity of QTc prolongation can be increased when Ebastine is combined with Moxifloxacin.
DB11770
The risk or severity of QTc prolongation can be increased when Talinolol is combined with Moxifloxacin.
DB11774
The risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Moxifloxacin.
DB11785
The risk or severity of QTc prolongation can be increased when Anisodamine is combined with Moxifloxacin.
DB11891
The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Moxifloxacin.
DB11892
The risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Moxifloxacin.
DB11943
The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Moxifloxacin.
DB12093
The risk or severity of QTc prolongation can be increased when Tetrahydropalmatine is combined with Moxifloxacin.
DB12231
The risk or severity of QTc prolongation can be increased when Temefos is combined with Moxifloxacin.
DB12245
The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Moxifloxacin.
DB12645
The risk or severity of QTc prolongation can be increased when Givinostat is combined with Moxifloxacin.
DB12712
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Moxifloxacin.
DB12766
The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Moxifloxacin.
DB12923
The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Moxifloxacin.
DB13358
The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Moxifloxacin.
DB13488
The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Moxifloxacin.
DB13555
The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Moxifloxacin.
DB13627
The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Moxifloxacin.
DB13651
The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Moxifloxacin.
DB13691
The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Moxifloxacin.
DB13744
The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Moxifloxacin.
DB13766
The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Moxifloxacin.
DB13772
The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Moxifloxacin.
DB13823
The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Moxifloxacin.
DB14185
The risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Moxifloxacin.
DB14713
The risk or severity of QTc prolongation can be increased when Inotersen is combined with Moxifloxacin.
DB01601
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Moxifloxacin.
DB00845
The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Moxifloxacin.
DB11796
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Moxifloxacin.
DB00540
The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Moxifloxacin.
DB01151
The risk or severity of QTc prolongation can be increased when Desipramine is combined with Moxifloxacin.
DB00751
The risk or severity of QTc prolongation can be increased when Epinastine is combined with Moxifloxacin.
DB11853
The risk or severity of QTc prolongation can be increased when Relugolix is combined with Moxifloxacin.
DB00176
The metabolism of Fluvoxamine can be decreased when combined with Moxifloxacin.
DB00184
The metabolism of Nicotine can be decreased when combined with Moxifloxacin.
DB00188
The metabolism of Bortezomib can be decreased when combined with Moxifloxacin.
DB00195
The metabolism of Betaxolol can be decreased when combined with Moxifloxacin.
DB00262
The metabolism of Carmustine can be decreased when combined with Moxifloxacin.
DB00281
The metabolism of Lidocaine can be decreased when combined with Moxifloxacin.
DB00286
The metabolism of Conjugated estrogens can be decreased when combined with Moxifloxacin.
DB00296
The metabolism of Ropivacaine can be decreased when combined with Moxifloxacin.
DB00316
The metabolism of Acetaminophen can be decreased when combined with Moxifloxacin.
DB00334
The metabolism of Olanzapine can be decreased when combined with Moxifloxacin.
DB00356
The metabolism of Chlorzoxazone can be decreased when combined with Moxifloxacin.
DB00363
The metabolism of Clozapine can be decreased when combined with Moxifloxacin.
DB00370
The metabolism of Mirtazapine can be decreased when combined with Moxifloxacin.
DB00379
The metabolism of Mexiletine can be decreased when combined with Moxifloxacin.
DB00382
The metabolism of Tacrine can be decreased when combined with Moxifloxacin.
DB00384
The metabolism of Triamterene can be decreased when combined with Moxifloxacin.
DB00420
The metabolism of Promazine can be decreased when combined with Moxifloxacin.
DB00425
The metabolism of Zolpidem can be decreased when combined with Moxifloxacin.
DB00442
The metabolism of Entecavir can be decreased when combined with Moxifloxacin.
DB00461
The metabolism of Nabumetone can be decreased when combined with Moxifloxacin.
DB00476
The metabolism of Duloxetine can be decreased when combined with Moxifloxacin.
DB00477
The metabolism of Chlorpromazine can be decreased when combined with Moxifloxacin.
DB00499
The metabolism of Flutamide can be decreased when combined with Moxifloxacin.
DB00518
The metabolism of Albendazole can be decreased when combined with Moxifloxacin.
DB00533
The metabolism of Rofecoxib can be decreased when combined with Moxifloxacin.
DB00568
The metabolism of Cinnarizine can be decreased when combined with Moxifloxacin.
DB00571
The metabolism of Propranolol can be decreased when combined with Moxifloxacin.
DB00586
The metabolism of Diclofenac can be decreased when combined with Moxifloxacin.
DB00629
The metabolism of Guanabenz can be decreased when combined with Moxifloxacin.
DB00642
The metabolism of Pemetrexed can be decreased when combined with Moxifloxacin.
DB00661
The metabolism of Verapamil can be decreased when combined with Moxifloxacin.
DB00730
The metabolism of Thiabendazole can be decreased when combined with Moxifloxacin.
DB00740
The metabolism of Riluzole can be decreased when combined with Moxifloxacin.
DB00744
The metabolism of Zileuton can be decreased when combined with Moxifloxacin.
DB00758
The metabolism of Clopidogrel can be decreased when combined with Moxifloxacin.
DB00783
The metabolism of Estradiol can be decreased when combined with Moxifloxacin.
DB00787
The metabolism of Acyclovir can be decreased when combined with Moxifloxacin.
DB00788
The metabolism of Naproxen can be decreased when combined with Moxifloxacin.
DB00831
The metabolism of Trifluoperazine can be decreased when combined with Moxifloxacin.
DB00850
The metabolism of Perphenazine can be decreased when combined with Moxifloxacin.
DB00857
The metabolism of Terbinafine can be decreased when combined with Moxifloxacin.
DB00863
The metabolism of Ranitidine can be decreased when combined with Moxifloxacin.
DB00898
The metabolism of Ethanol can be decreased when combined with Moxifloxacin.
DB00934
The metabolism of Maprotiline can be decreased when combined with Moxifloxacin.
DB00969
The metabolism of Alosetron can be decreased when combined with Moxifloxacin.
DB00978
The metabolism of Lomefloxacin can be decreased when combined with Moxifloxacin.
DB00980
The metabolism of Ramelteon can be decreased when combined with Moxifloxacin.
DB00993
The metabolism of Azathioprine can be decreased when combined with Moxifloxacin.
DB00998
The metabolism of Frovatriptan can be decreased when combined with Moxifloxacin.
DB01002
The metabolism of Levobupivacaine can be decreased when combined with Moxifloxacin.
DB01012
The metabolism of Cinacalcet can be decreased when combined with Moxifloxacin.
DB01037
The metabolism of Selegiline can be decreased when combined with Moxifloxacin.
DB01056
The metabolism of Tocainide can be decreased when combined with Moxifloxacin.
DB01058
The metabolism of Praziquantel can be decreased when combined with Moxifloxacin.
DB01065
The metabolism of Melatonin can be decreased when combined with Moxifloxacin.
DB01087
The metabolism of Primaquine can be decreased when combined with Moxifloxacin.
DB01094
The metabolism of Hesperetin can be decreased when combined with Moxifloxacin.
DB01097
The metabolism of Leflunomide can be decreased when combined with Moxifloxacin.
DB01115
The metabolism of Nifedipine can be decreased when combined with Moxifloxacin.
DB01136
The metabolism of Carvedilol can be decreased when combined with Moxifloxacin.
DB01166
The metabolism of Cilostazol can be decreased when combined with Moxifloxacin.
DB01182
The metabolism of Propafenone can be decreased when combined with Moxifloxacin.
DB01191
The metabolism of Dexfenfluramine can be decreased when combined with Moxifloxacin.
DB01367
The metabolism of Rasagiline can be decreased when combined with Moxifloxacin.
DB01424
The metabolism of Aminophenazone can be decreased when combined with Moxifloxacin.
DB01435
The metabolism of Antipyrine can be decreased when combined with Moxifloxacin.
DB01558
The metabolism of Bromazepam can be decreased when combined with Moxifloxacin.
DB01623
The metabolism of Thiothixene can be decreased when combined with Moxifloxacin.
DB01628
The metabolism of Etoricoxib can be decreased when combined with Moxifloxacin.
DB01645
The metabolism of Genistein can be decreased when combined with Moxifloxacin.
DB02709
The metabolism of Resveratrol can be decreased when combined with Moxifloxacin.
DB03783
The metabolism of Phenacetin can be decreased when combined with Moxifloxacin.
DB04574
The metabolism of Estrone sulfate can be decreased when combined with Moxifloxacin.
DB04841
The metabolism of Flunarizine can be decreased when combined with Moxifloxacin.
DB04871
The metabolism of Lorcaserin can be decreased when combined with Moxifloxacin.
DB04948
The metabolism of Lofexidine can be decreased when combined with Moxifloxacin.
DB05676
The metabolism of Apremilast can be decreased when combined with Moxifloxacin.
DB06148
The metabolism of Mianserin can be decreased when combined with Moxifloxacin.
DB06210
The metabolism of Eltrombopag can be decreased when combined with Moxifloxacin.
DB06235
The metabolism of Vadimezan can be decreased when combined with Moxifloxacin.
DB06589
The metabolism of Pazopanib can be decreased when combined with Moxifloxacin.
DB06770
The metabolism of Benzyl alcohol can be decreased when combined with Moxifloxacin.
DB06774
The metabolism of Capsaicin can be decreased when combined with Moxifloxacin.
DB08883
The metabolism of Perampanel can be decreased when combined with Moxifloxacin.
DB09071
The metabolism of Tasimelteon can be decreased when combined with Moxifloxacin.
DB09118
The metabolism of Stiripentol can be decreased when combined with Moxifloxacin.
DB09225
The metabolism of Zotepine can be decreased when combined with Moxifloxacin.
DB09288
The metabolism of Propacetamol can be decreased when combined with Moxifloxacin.
DB09290
The metabolism of Ramosetron can be decreased when combined with Moxifloxacin.
DB11967
The metabolism of Binimetinib can be decreased when combined with Moxifloxacin.
DB12026
The metabolism of Voxilaprevir can be decreased when combined with Moxifloxacin.
DB12332
The metabolism of Rucaparib can be decreased when combined with Moxifloxacin.
DB12945
The metabolism of Dihydralazine can be decreased when combined with Moxifloxacin.
DB13952
The metabolism of Estradiol acetate can be decreased when combined with Moxifloxacin.
DB13953
The metabolism of Estradiol benzoate can be decreased when combined with Moxifloxacin.
DB13954
The metabolism of Estradiol cypionate can be decreased when combined with Moxifloxacin.
DB13955
The metabolism of Estradiol dienanthate can be decreased when combined with Moxifloxacin.
DB13956
The metabolism of Estradiol valerate can be decreased when combined with Moxifloxacin.
DB00715
The metabolism of Paroxetine can be decreased when combined with Moxifloxacin.
DB11757
The metabolism of Istradefylline can be decreased when combined with Moxifloxacin.
DB00972
The metabolism of Azelastine can be decreased when combined with Moxifloxacin.
DB04889
The metabolism of Bicifadine can be decreased when combined with Moxifloxacin.
DB05708
The metabolism of GTS-21 can be decreased when combined with Moxifloxacin.
DB00977
The metabolism of Ethinylestradiol can be decreased when combined with Moxifloxacin.
DB01142
The metabolism of Doxepin can be decreased when combined with Moxifloxacin.
DB00532
The metabolism of Mephenytoin can be decreased when combined with Moxifloxacin.
DB00924
The metabolism of Cyclobenzaprine can be decreased when combined with Moxifloxacin.
DB11689
The metabolism of Selumetinib can be decreased when combined with Moxifloxacin.
DB00655
The metabolism of Estrone can be decreased when combined with Moxifloxacin.
DB00299
The metabolism of Penciclovir can be decreased when combined with Moxifloxacin.
DB00277
The metabolism of Theophylline can be decreased when combined with Moxifloxacin.
DB01223
The metabolism of Aminophylline can be decreased when combined with Moxifloxacin.
DB00201
The metabolism of Caffeine can be decreased when combined with Moxifloxacin.
DB00651
The metabolism of Dyphylline can be decreased when combined with Moxifloxacin.
DB00806
The metabolism of Pentoxifylline can be decreased when combined with Moxifloxacin.
DB01033
The metabolism of Mercaptopurine can be decreased when combined with Moxifloxacin.
DB01303
The metabolism of Oxtriphylline can be decreased when combined with Moxifloxacin.
DB01412
The metabolism of Theobromine can be decreased when combined with Moxifloxacin.
DB01482
The metabolism of Fenethylline can be decreased when combined with Moxifloxacin.
DB01667
The metabolism of 8-azaguanine can be decreased when combined with Moxifloxacin.
DB01978
The metabolism of 7,9-Dimethylguanine can be decreased when combined with Moxifloxacin.
DB02134
The metabolism of Xanthine can be decreased when combined with Moxifloxacin.
DB02245
The metabolism of 7-Deazaguanine can be decreased when combined with Moxifloxacin.
DB02377
The metabolism of Guanine can be decreased when combined with Moxifloxacin.
DB02489
The metabolism of 9-Methylguanine can be decreased when combined with Moxifloxacin.
DB02568
The metabolism of Peldesine can be decreased when combined with Moxifloxacin.
DB04076
The metabolism of Hypoxanthine can be decreased when combined with Moxifloxacin.
DB04356
The metabolism of 9-Deazaguanine can be decreased when combined with Moxifloxacin.
DB06479
The metabolism of Propentofylline can be decreased when combined with Moxifloxacin.
DB06575
The metabolism of Valomaciclovir can be decreased when combined with Moxifloxacin.
DB07954
The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Moxifloxacin.
DB08844
The metabolism of Uric acid can be decreased when combined with Moxifloxacin.
DB09273
The metabolism of Doxofylline can be decreased when combined with Moxifloxacin.
DB11919
The metabolism of 6-O-benzylguanine can be decreased when combined with Moxifloxacin.
DB12406
The metabolism of Lisofylline can be decreased when combined with Moxifloxacin.
DB12531
The metabolism of Lobucavir can be decreased when combined with Moxifloxacin.
DB12926
The metabolism of Cafedrine can be decreased when combined with Moxifloxacin.
DB12927
The metabolism of Theodrenaline can be decreased when combined with Moxifloxacin.
DB13203
The metabolism of Bamifylline can be decreased when combined with Moxifloxacin.
DB13449
The metabolism of Proxyphylline can be decreased when combined with Moxifloxacin.
DB13573
The metabolism of Acefylline can be decreased when combined with Moxifloxacin.
DB13592
The metabolism of Etamiphylline can be decreased when combined with Moxifloxacin.
DB13634
The metabolism of Pentifylline can be decreased when combined with Moxifloxacin.
DB13812
The metabolism of Bufylline can be decreased when combined with Moxifloxacin.
DB14018
The metabolism of Bromotheophylline can be decreased when combined with Moxifloxacin.
DB14029
The metabolism of Furafylline can be decreased when combined with Moxifloxacin.
DB14132
The metabolism of 8-chlorotheophylline can be decreased when combined with Moxifloxacin.
DB15122
The metabolism of PCS-499 can be decreased when combined with Moxifloxacin.
DB12768
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Moxifloxacin.
DB14022
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Moxifloxacin.
DB11637
Moxifloxacin may increase the QTc-prolonging activities of Delamanid.
DB00675
The metabolism of Moxifloxacin can be decreased when combined with Tamoxifen.
DB00398
The metabolism of Sorafenib can be decreased when combined with Moxifloxacin.
DB00544
The metabolism of Fluorouracil can be decreased when combined with Moxifloxacin.
DB00773
The metabolism of Etoposide can be decreased when combined with Moxifloxacin.
DB00851
The metabolism of Dacarbazine can be decreased when combined with Moxifloxacin.
DB01254
The metabolism of Dasatinib can be decreased when combined with Moxifloxacin.
DB06626
The metabolism of Axitinib can be decreased when combined with Moxifloxacin.
DB06769
The metabolism of Bendamustine can be decreased when combined with Moxifloxacin.
DB08910
The metabolism of Pomalidomide can be decreased when combined with Moxifloxacin.
DB09256
The metabolism of Tegafur can be decreased when combined with Moxifloxacin.
DB13874
The metabolism of Enasidenib can be decreased when combined with Moxifloxacin.
DB00458
The metabolism of Imipramine can be decreased when combined with Moxifloxacin.
DB00575
The metabolism of Clonidine can be decreased when combined with Moxifloxacin.
DB01242
The metabolism of Clomipramine can be decreased when combined with Moxifloxacin.
DB00301
The serum concentration of Moxifloxacin can be increased when it is combined with Flucloxacillin.
DB00319
The serum concentration of Moxifloxacin can be increased when it is combined with Piperacillin.
DB00415
The serum concentration of Moxifloxacin can be increased when it is combined with Ampicillin.
DB00417
The serum concentration of Moxifloxacin can be increased when it is combined with Phenoxymethylpenicillin.
DB00485
The serum concentration of Moxifloxacin can be increased when it is combined with Dicloxacillin.
DB00578
The serum concentration of Moxifloxacin can be increased when it is combined with Carbenicillin.
DB00607
The serum concentration of Moxifloxacin can be increased when it is combined with Nafcillin.
DB00713
The serum concentration of Moxifloxacin can be increased when it is combined with Oxacillin.
DB00739
The serum concentration of Moxifloxacin can be increased when it is combined with Hetacillin.
DB00895
The serum concentration of Moxifloxacin can be increased when it is combined with Benzylpenicilloyl polylysine.
DB00948
The serum concentration of Moxifloxacin can be increased when it is combined with Mezlocillin.
DB01000
The serum concentration of Moxifloxacin can be increased when it is combined with Cyclacillin.
DB01053
The serum concentration of Moxifloxacin can be increased when it is combined with Benzylpenicillin.
DB01060
The serum concentration of Moxifloxacin can be increased when it is combined with Amoxicillin.
DB01061
The serum concentration of Moxifloxacin can be increased when it is combined with Azlocillin.
DB01147
The serum concentration of Moxifloxacin can be increased when it is combined with Cloxacillin.
DB01163
The serum concentration of Moxifloxacin can be increased when it is combined with Amdinocillin.
DB01602
The serum concentration of Moxifloxacin can be increased when it is combined with Bacampicillin.
DB01603
The serum concentration of Moxifloxacin can be increased when it is combined with Meticillin.
DB01604
The serum concentration of Moxifloxacin can be increased when it is combined with Pivampicillin.
DB01605
The serum concentration of Moxifloxacin can be increased when it is combined with Pivmecillinam.
DB01607
The serum concentration of Moxifloxacin can be increased when it is combined with Ticarcillin.
DB08795
The serum concentration of Moxifloxacin can be increased when it is combined with Azidocillin.
DB09319
The serum concentration of Moxifloxacin can be increased when it is combined with Carindacillin.
DB09320
The serum concentration of Moxifloxacin can be increased when it is combined with Procaine benzylpenicillin.
DB12127
The serum concentration of Moxifloxacin can be increased when it is combined with Sultamicillin.
DB12343
The serum concentration of Moxifloxacin can be increased when it is combined with Temocillin.
DB13300
The serum concentration of Moxifloxacin can be increased when it is combined with Epicillin.
DB13337
The serum concentration of Moxifloxacin can be increased when it is combined with Pheneticillin.
DB13506
The serum concentration of Moxifloxacin can be increased when it is combined with Carfecillin.
DB13660
The serum concentration of Moxifloxacin can be increased when it is combined with Propicillin.
DB13686
The serum concentration of Moxifloxacin can be increased when it is combined with Clometocillin.
DB13693
The serum concentration of Moxifloxacin can be increased when it is combined with Sulbenicillin.
DB13739
The serum concentration of Moxifloxacin can be increased when it is combined with Penamecillin.
DB13814
The serum concentration of Moxifloxacin can be increased when it is combined with Talampicillin.
DB13816
The serum concentration of Moxifloxacin can be increased when it is combined with Aspoxicillin.
DB13836
The serum concentration of Moxifloxacin can be increased when it is combined with Metampicillin.
DB00321
Moxifloxacin may increase the QTc-prolonging activities of Amitriptyline.
DB00091
The risk or severity of nephrotoxicity can be increased when Moxifloxacin is combined with Cyclosporine.
DB00268
The risk or severity of adverse effects can be increased when Moxifloxacin is combined with Ropinirole.
DB00581
The therapeutic efficacy of Lactulose can be decreased when used in combination with Moxifloxacin.
DB00656
The risk or severity of QTc prolongation can be increased when Trazodone is combined with Moxifloxacin.
DB11986
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Entrectinib.
DB11642
Moxifloxacin may increase the QTc-prolonging activities of Pitolisant.
DB12825
Lefamulin may increase the QTc-prolonging activities of Moxifloxacin.
DB00557
The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Moxifloxacin.
DB00246
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ziprasidone.
DB14513
Magnesium can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00502
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Haloperidol.
DB14443
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Moxifloxacin.
DB00472
The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Fluoxetine.

序列

实验性质

Melting Point
238-242 °C

logP
2.9

外部标识符

resource：Drugs Product Database (DPD)
identifier：12034
resource：ChEBI
identifier：63611
resource：PubChem Compound
identifier：152946
resource：PubChem Substance
identifier：46508509
resource：KEGG Compound
identifier：C07663
resource：KEGG Drug
identifier：D08237
resource：ChemSpider
identifier：134802
resource：BindingDB
identifier：50366824
resource：PharmGKB
identifier：PA450555
resource：PDB
identifier：MFX
resource：Therapeutic Targets Database
identifier：DAP000158
resource：Wikipedia
identifier：Moxifloxacin
resource：ChEMBL
identifier：CHEMBL32
resource：ZINC
identifier：ZINC000003826253
resource：RxCUI
identifier：139462

外部链接

RxList
http://www.rxlist.com/cgi/generic3/vigamox.htm
PDRhealth
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ave1540.shtml
Drugs.com
http://www.drugs.com/cdi/moxifloxacin-drops.html

路径

目标

id:BE0000429
name:DNA topoisomerase 4 subunit A
organism:Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
action:inhibitor
Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
Schafer J, Hovde LB, Simonson D, Rotschafer JC: In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant. Diagn Microbiol Infect Dis. 2008 Feb;60(2):155-61. Epub 2007 Oct 29.
Deryke CA, Du X, Nicolau DP: Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae. J Antimicrob Chemother. 2006 Sep;58(3):601-9. Epub 2006 Jul 19.
Perez-Vazquez M, Roman F, Aracil B, Canton R, Campos J: Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations. J Clin Microbiol. 2004 Mar;42(3):1185-91.
known-action:yes
name:DNA topoisomerase 4 subunit A
general-function:Dna topoisomerase type ii (atp-hydrolyzing) activity
specific-function:Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
gene-name:parC
locus:
cellular-location:Cell membrane
transmembrane-regions:
signal-regions:
theoretical-pi:6.42
molecular-weight:83366.24
chromosome-location:
organism:Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
external-identifiers:GenBank Gene DatabaseL42023GenBank Protein Database1574370UniProtKBP43702UniProt AccessionPARC_HAEIN
synonyms:5.99.1.3Topoisomerase IV subunit A
amino-acid-sequence:>lcl|BSEQ0010299|DNA topoisomerase 4 subunit A MTNINYEGIEQMPLRTFTEKAYLNYSMYVIMDRALPFIGDGLKPVQRRIVYAMSELGLNA TAKYKKSARTVGDVLGKFHPHGDSACYEAMVLMAQPFSYRYPLVDGQGNWGAPDDPKSFA AMRYTESRLSKISEILLNELGQGTVDYQPNFDGTLAEPQYLPARLPHILLNGTTGIAVGM ATDIPPHNINEIADAAVMLLDNPKAGLDDVLEIVQGPDFPTEAEIISPKSEIRKIYEQGR GSIKMRATWKKEDGEIIISALPHQSSPSKVIAQIAEQMTAKKLPMLEDIRDEADHENPIR IVLVPRSNRVDTDALMAHLFATTDLEKSYRVNMNMIGLDHKPAVKGLLEILNEWLDFRRT TVTRRLQYRLDKVLSRLHILEGLMIAFLNIDEVIEIIRHEDDPKAELMARFNLSDEQADA ILNLRLRHLAKLEENQLKAEQDELEKERLNLEAILGSERRLNTLIKKEIQEDAKKYANPR MSQLVEREEAKMISESDMTPAEPVTVILSEMGWVRCAKGHDIDPKSLSYKAGDSYLAHAC GKSNQAVVFIDSTGRSYALDPLSLPSARSQGEPLTGKLNLPTGATIEYVVMASEQQELLM ASDAGYGFICKFEDLIARNKAGKALISLPENAKVLKPKTLINSTALVVAITSAGRMLIFP AQDLPVLSKGKGNKMITIPAANAKDRSELLTKLLLISDQASLEFYSGKRKIVLKPEDLQK FRAERGRKGSTLPRGLHTNLEIMVIEP
gene-sequence:>lcl|BSEQ0010300|DNA topoisomerase 4 subunit A (parC) ATGACAAATATCAACTATGAAGGCATTGAGCAAATGCCTCTACGCACCTTCACTGAAAAG GCTTATCTCAACTATTCTATGTATGTCATCATGGATCGTGCGTTGCCTTTTATCGGTGAT GGTTTAAAACCCGTTCAACGTCGTATTGTATATGCGATGTCTGAACTTGGCTTAAATGCC ACGGCAAAATACAAAAAATCTGCTCGTACCGTCGGTGATGTACTCGGTAAATTCCATCCA CATGGTGACAGTGCTTGTTATGAAGCTATGGTGTTAATGGCACAACCCTTCTCTTATCGT TATCCACTTGTAGATGGTCAAGGTAACTGGGGGGCACCAGATGATCCAAAATCCTTCGCA GCCATGCGTTATACGGAATCTCGCCTATCTAAAATCTCTGAAATCTTGTTGAATGAACTC GGACAAGGAACAGTAGATTATCAACCAAACTTTGATGGAACCTTGGCTGAACCACAATAT TTACCTGCTCGTTTACCGCATATTTTATTGAACGGCACAACAGGTATTGCGGTGGGGATG GCCACAGATATTCCACCACACAATATTAACGAAATTGCTGATGCGGCAGTAATGTTGCTA GATAATCCTAAAGCGGGATTAGATGATGTACTTGAAATTGTTCAAGGCCCAGATTTTCCA ACAGAAGCGGAAATTATTTCGCCAAAATCAGAAATTCGTAAAATTTATGAGCAAGGTCGT GGCTCAATAAAAATGCGTGCAACTTGGAAAAAAGAAGACGGTGAAATTATTATTTCAGCG CTTCCACATCAATCTTCGCCATCCAAAGTCATTGCACAAATAGCCGAACAAATGACGGCA AAAAAACTGCCAATGCTAGAAGATATTCGAGATGAAGCCGATCACGAAAATCCAATTCGC ATTGTGCTAGTTCCTCGCTCAAATCGCGTCGATACTGATGCCTTAATGGCACATTTATTT GCGACCACAGATCTTGAAAAAAGCTACCGTGTAAATATGAATATGATCGGGCTTGATCAT AAACCAGCGGTAAAAGGCTTATTAGAAATCTTAAATGAATGGCTTGACTTCCGTCGCACA ACGGTCACTCGTCGCCTTCAATATCGCCTAGATAAAGTGCTCTCTCGCTTGCATATTTTA GAAGGCTTGATGATAGCCTTTTTAAATATTGATGAAGTTATCGAAATTATACGCCACGAA GATGATCCAAAAGCAGAGCTTATGGCACGCTTTAATTTAAGCGATGAACAAGCCGATGCC ATTTTAAATTTACGCTTACGTCATTTAGCGAAATTAGAAGAAAACCAACTCAAAGCAGAA CAAGATGAACTTGAAAAAGAGCGGTTAAATTTAGAAGCAATTTTAGGATCAGAACGCCGT TTGAATACGCTTATCAAAAAAGAAATTCAAGAAGATGCGAAAAAATATGCCAATCCACGT ATGTCTCAACTGGTCGAACGTGAAGAAGCCAAAATGATCTCTGAAAGTGATATGACACCA GCAGAACCAGTTACTGTCATCTTATCAGAAATGGGCTGGGTACGTTGTGCAAAAGGACAC GATATTGATCCTAAATCATTAAGCTACAAAGCTGGTGATAGCTATCTAGCTCACGCTTGT GGCAAAAGTAATCAAGCCGTTGTATTCATTGATAGCACGGGGCGGAGTTATGCACTCGAT CCGCTTTCCTTGCCTTCCGCTCGCTCCCAAGGCGAACCACTTACAGGTAAACTCAATTTA CCCACTGGTGCGACCATTGAATATGTTGTAATGGCCAGCGAACAGCAAGAATTATTGATG GCTTCTGATGCAGGATATGGTTTTATTTGTAAATTTGAAGATTTAATTGCACGTAACAAG GCTGGAAAAGCCTTGATTTCTTTACCAGAAAATGCCAAAGTGTTGAAGCCTAAAACATTG ATAAATTCTACCGCACTTGTTGTCGCAATCACATCAGCAGGCAGAATGTTGATTTTTCCA GCACAGGATTTACCGGTATTATCAAAAGGTAAAGGCAATAAAATGATCACTATTCCCGCA GCGAATGCAAAAGATCGTAGCGAACTATTGACAAAATTATTGCTTATTTCAGATCAAGCA AGTCTTGAATTTTATTCTGGAAAACGAAAAATTGTATTAAAACCAGAAGATCTGCAAAAG TTCCGCGCAGAACGAGGCAGAAAAGGTTCGACATTACCACGTGGATTACATACCAATCTT GAAATTATGGTAATCGAGCCGTAA
pfams:PF03989DNA_gyraseA_CPF00521DNA_topoisoIV
go-classifiers:componentchromosomecomponentextrinsic component of plasma membranefunctionATP bindingfunctionDNA bindingfunctionDNA topoisomerase type II (ATP-hydrolyzing) activityprocesschromosome segregationprocessDNA topological change
id:BE0000366
name:DNA gyrase subunit A
organism:Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
action:inhibitor
Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4.
Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Kohrer K, Schmitz FJ: Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother. 1999 Aug;43(8):2051-5.
Dridi L, Tankovic J, Burghoffer B, Barbut F, Petit JC: gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile. Antimicrob Agents Chemother. 2002 Nov;46(11):3418-21.
known-action:yes
name:DNA gyrase subunit A
general-function:Dna topoisomerase type ii (atp-hydrolyzing) activity
specific-function:DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings.
gene-name:gyrA
locus:
cellular-location:Cytoplasm
transmembrane-regions:
signal-regions:
theoretical-pi:4.85
molecular-weight:97817.145
chromosome-location:
organism:Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
external-identifiers:GenBank Gene DatabaseL42023GenBank Protein Database1574722UniProtKBP43700UniProt AccessionGYRA_HAEIN
synonyms:5.99.1.3
amino-acid-sequence:>lcl|BSEQ0010114|DNA gyrase subunit A MTDSIQSSITPVNIEEELKSSYLDYAMSVIVGRALPDVRDGLKPVHRRVLFSMDREGNTA NKKYVKSARVVGDVIGKYHPHGDSAVYDTIVRMAQPFSLRYMLVDGQGNFGSIDGDAPAA MRYTEVRMQKITQALLTDLDKETVNFSPNYDGELMIPDVLPTRIPALLANGSSGIAVGMA TNIPPHNLNEVLNGCLAYIDKNEITIDELMQHIPGPDFPTAALINGRKGIEEAYRTGRGK VYVRARATVETNEKGREQIIVSELPYQVNKAKLVEKIAELIREKKIEGISNITDLSNKEG IRIEIDIKRDAVGEVVLNHLYSLTQMQVTFGINMVALDHGQPRLFNLKEIIEAFVLHRRE VVTRRSIFELRKARERTHILEGLAVARSNIDEMIAIIRNSKNREEAATSISSRSWTLHSD IINLLDASARPDELEENLGIQGEQYYLSPAQVNAILELRLHRLTGIAFEEVIKEYEELLV KIADLLHILSSAERLMEVIREELEEVKAQFGDDRLTEITAASGDIDLEDLIAQEDVVVTL SHEGYVKYQPLTDYEAQRRGGKGKSATKMKEEDFIEKLLVANTHDTILCFSSRGRLYWLK VYQLPQASRGARGRPIVNILPLQENERITAILPVSAYEEDKFVVMATAGGIVKKIALTEF SRPRSNGIIALNLRDEDELIGVDITDGSNEIMLFSSQGRVVRFAENAVRAMGRLATGVRG IKLALTNDISDDESAVEIEDISDDNAEASLDLNIDKVVSLVVPKGEGAILTATQNGYGKR TQLSEYPTKSRNTKGVISIKVSERNGKVVAATQVEETDQIMLITDAGTLVRTRVSEVSIV GRNTQGVRLIRTADDEHVVSLERVCDADEDDSLEESSSEE
gene-sequence:>lcl|BSEQ0010115|DNA gyrase subunit A (gyrA) ATGACGGATTCAATCCAATCATCTATCACCCCTGTCAATATCGAAGAAGAACTTAAATCT TCCTACCTTGACTACGCGATGTCGGTTATCGTTGGGCGTGCATTACCTGACGTTCGAGAT GGTTTAAAACCTGTTCACCGCCGCGTACTATTCTCAATGGATCGCGAAGGCAATACCGCC AATAAAAAATACGTAAAATCAGCGCGTGTTGTGGGTGATGTAATCGGTAAATATCACCCG CATGGTGACTCCGCCGTGTACGATACCATCGTTCGTATGGCACAACCCTTCTCACTTCGC TATATGTTGGTTGATGGGCAAGGTAACTTTGGTTCAATTGATGGTGATGCGCCAGCTGCA ATGCGTTATACCGAAGTACGTATGCAAAAAATTACGCAAGCATTGCTCACGGATTTGGAT AAAGAAACCGTCAATTTCTCGCCAAACTATGATGGCGAATTAATGATTCCAGATGTATTG CCGACTCGTATTCCAGCACTGTTAGCAAATGGTTCTTCTGGTATTGCGGTGGGGATGGCA ACTAACATTCCCCCTCACAACTTAAACGAAGTATTAAATGGTTGTTTGGCTTATATTGAC AAAAATGAAATTACCATTGATGAATTAATGCAACATATTCCAGGGCCTGACTTCCCAACG GCTGCGTTAATTAATGGTCGTAAAGGGATTGAAGAGGCCTATCGCACTGGTCGTGGTAAA GTGTATGTTCGTGCTCGTGCAACGGTAGAAACCAACGAAAAAGGACGCGAGCAAATTATC GTGTCTGAATTGCCATACCAAGTAAATAAAGCAAAATTAGTCGAGAAAATCGCCGAATTA ATTCGCGAGAAAAAAATCGAAGGTATCAGCAATATTACTGACCTTTCAAATAAAGAAGGG ATCCGTATTGAAATTGATATTAAACGTGATGCAGTGGGGGAAGTGGTATTAAACCATCTT TACTCACTCACTCAAATGCAAGTGACCTTTGGTATCAATATGGTGGCATTGGATCACGGT CAGCCACGTTTATTTAATCTTAAAGAAATTATTGAAGCCTTTGTTTTACACCGCCGTGAA GTGGTTACACGTCGTTCTATCTTTGAGCTTCGCAAAGCACGTGAACGTACGCATATTTTG GAAGGTTTAGCGGTTGCTCGTTCTAATATCGATGAAATGATTGCGATCATTCGTAACTCT AAAAACCGTGAAGAAGCCGCAACATCAATCAGTTCACGCTCTTGGACGTTACATAGCGAT ATTATTAATCTTCTTGATGCTTCTGCTCGTCCTGATGAGTTAGAAGAAAATCTTGGTATT CAAGGCGAACAATATTACTTATCGCCAGCGCAAGTAAACGCAATTCTAGAACTTCGCTTA CACCGTTTAACGGGCATTGCGTTTGAAGAAGTTATAAAAGAATATGAAGAATTATTAGTT AAAATTGCGGATCTTCTTCATATTTTAAGTAGTGCAGAACGTTTAATGGAAGTAATTCGT GAAGAATTGGAAGAAGTAAAAGCACAATTTGGTGATGATCGTTTAACTGAAATTACCGCT GCTTCTGGCGATATTGATTTAGAAGATTTAATCGCACAAGAAGACGTGGTTGTGACGCTT TCTCACGAAGGTTATGTGAAATACCAACCACTGACTGACTATGAAGCACAACGCCGTGGC GGTAAAGGCAAATCTGCAACGAAGATGAAAGAAGAAGATTTCATCGAAAAATTACTGGTA GCAAATACTCACGATACCATCCTCTGCTTCTCTAGCCGTGGTCGTTTATATTGGTTGAAA GTATATCAACTTCCGCAAGCGAGCCGTGGCGCACGCGGTCGTCCAATTGTGAATATTCTT CCGTTACAAGAAAACGAACGTATTACTGCAATCTTGCCAGTTTCTGCTTACGAAGAAGAT AAATTCGTAGTCATGGCAACTGCTGGCGGTATTGTGAAGAAAATCGCCTTAACCGAATTT AGCCGTCCACGTTCAAACGGTATCATCGCATTGAATTTACGTGACGAAGATGAATTAATC GGCGTGGATATTACTGATGGCAGCAACGAAATTATGTTGTTCTCATCACAAGGTCGCGTG GTGCGTTTTGCTGAAAATGCCGTGCGTGCGATGGGGCGTTTAGCAACAGGTGTTCGCGGT ATCAAACTGGCTTTAACAAACGATATTTCTGACGATGAAAGTGCGGTAGAAATTGAAGAT ATTTCTGATGACAACGCTGAAGCATCATTAGACTTAAATATCGATAAAGTGGTCTCGCTC GTTGTGCCAAAAGGTGAAGGGGCAATTTTAACCGCAACGCAAAACGGCTACGGAAAACGC ACACAATTAAGTGAATACCCAACTAAATCACGTAATACAAAAGGTGTGATTTCGATTAAA GTGAGTGAACGCAATGGTAAAGTCGTTGCCGCAACTCAAGTAGAAGAAACAGACCAAATT ATGTTGATCACTGATGCAGGAACCCTTGTTCGCACACGCGTAAGCGAAGTGAGCATTGTA GGGCGTAACACGCAAGGTGTTCGCTTAATTCGTACTGCCGATGATGAACACGTAGTAAGT TTAGAACGTGTTTGTGATGCAGATGAAGATGATTCTTTGGAAGAAAGCAGTTCTGAAGAA TAA
pfams:PF03989DNA_gyraseA_CPF00521DNA_topoisoIV
go-classifiers:componentchromosomecomponentcytoplasmfunctionATP bindingfunctionDNA bindingfunctionDNA topoisomerase type II (ATP-hydrolyzing) activityprocessDNA topological changeprocessDNA-dependent DNA replication
id:BE0000742
name:DNA topoisomerase 2-alpha
organism:Humans
action:inhibitor
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
Reuveni D, Halperin D, Shalit I, Priel E, Fabian I: Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 2010 Aug;37(2):463-71.
Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, Leydon VR, Miles TJ, Pearson ND, Perera RL, Shillings AJ, Gwynn MN, Bax BD: Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. doi: 10.1038/nsmb.1892. Epub 2010 Aug 29.
known-action:unknown
name:DNA topoisomerase 2-alpha
general-function:Ubiquitin binding
specific-function:Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
gene-name:TOP2A
locus:17q21-q22
cellular-location:Cytoplasm
transmembrane-regions:
signal-regions:
theoretical-pi:9.17
molecular-weight:174383.88
chromosome-location:17
organism:Humans
external-identifiers:HUGO Gene Nomenclature Committee (HGNC)HGNC:11989GenAtlasTOP2AGenBank Gene DatabaseJ04088GenBank Protein Database292830Guide to Pharmacology2637UniProtKBP11388UniProt AccessionTOP2A_HUMAN
synonyms:5.99.1.3DNA topoisomerase II, alpha isozymeTOP2
amino-acid-sequence:>lcl|BSEQ0001480|DNA topoisomerase 2-alpha MEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTYIGSVELVTQQ MWVYDEDVGINYREVTFVPGLYKIFDEILVNAADNKQRDPKMSCIRVTIDPENNLISIWN NGKGIPVVEHKVEKMYVPALIFGQLLTSSNYDDDEKKVTGGRNGYGAKLCNIFSTKFTVE TASREYKKMFKQTWMDNMGRAGEMELKPFNGEDYTCITFQPDLSKFKMQSLDKDIVALMV RRAYDIAGSTKDVKVFLNGNKLPVKGFRSYVDMYLKDKLDETGNSLKVIHEQVNHRWEVC LTMSEKGFQQISFVNSIATSKGGRHVDYVADQIVTKLVDVVKKKNKGGVAVKAHQVKNHM WIFVNALIENPTFDSQTKENMTLQPKSFGSTCQLSEKFIKAAIGCGIVESILNWVKFKAQ VQLNKKCSAVKHNRIKGIPKLDDANDAGGRNSTECTLILTEGDSAKTLAVSGLGVVGRDK YGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYKKNYEDEDSLKTLRYGKIMIMT DQDQDGSHIKGLLINFIHHNWPSLLRHRFLEEFITPIVKVSKNKQEMAFYSLPEFEEWKS STPNHKKWKVKYYKGLGTSTSKEAKEYFADMKRHRIQFKYSGPEDDAAISLAFSKKQIDD RKEWLTNFMEDRRQRKLLGLPEDYLYGQTTTYLTYNDFINKELILFSNSDNERSIPSMVD GLKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSSYHHGEMSLMMTIINLAQNFVGSNN LNLLQPIGQFGTRLHGGKDSASPRYIFTMLSSLARLLFPPKDDHTLKFLYDDNQRVEPEW YIPIIPMVLINGAEGIGTGWSCKIPNFDVREIVNNIRRLMDGEEPLPMLPSYKNFKGTIE ELAPNQYVISGEVAILNSTTIEISELPVRTWTQTYKEQVLEPMLNGTEKTPPLITDYREY HTDTTVKFVVKMTEEKLAEAERVGLHKVFKLQTSLTCNSMVLFDHVGCLKKYDTVLDILR DFFELRLKYYGLRKEWLLGMLGAESAKLNNQARFILEKIDGKIIIENKPKKELIKVLIQR GYDSDPVKAWKEAQQKVPDEEENEESDNEKETEKSDSVTDSGPTFNYLLDMPLWYLTKEK KDELCRLRNEKEQELDTLKRKSPSDLWKEDLATFIEELEAVEAKEKQDEQVGLPGKGGKA KGKKTQMAEVLPSPRGQRVIPRITIEMKAEAEKKNKKKIKNENTEGSPQEDGVELEGLKQ RLEKKQKREPGTKTKKQTTLAFKPIKKGKKRNPWSDSESDRSSDESNFDVPPRETEPRRA ATKTKFTMDLDSDEDFSDFDEKTDDEDFVPSDASPPKTKTSPKLSNKELKPQKSVVSDLE ADDVKGSVPLSSSPPATHFPDETEITNPVPKKNVTVKKTAAKSQSSTSTTGAKKRAAPKG TKRDPALNSGVSQKPDPAKTKNRRKRKPSTSDDSDSNFEKIVSKAVTSKKSKGESDDFHM DFDSAVAPRAKSVRAKKPIKYLEESDEDDLF
gene-sequence:>lcl|BSEQ0019005|DNA topoisomerase 2-alpha (TOP2A) ATGGAAGTGTCACCATTGCAGCCTGTAAATGAAAATATGCAAGTCAACAAAATAAAGAAA AATGAAGATGCTAAGAAAAGACTGTCTGTTGAAAGAATCTATCAAAAGAAAACACAATTG GAACATATTTTGCTCCGCCCAGACACCTACATTGGTTCTGTGGAATTAGTGACCCAGCAA ATGTGGGTTTACGATGAAGATGTTGGCATTAACTATAGGGAAGTCACTTTTGTTCCTGGT TTGTACAAAATCTTTGATGAGATTCTAGTTAATGCTGCGGACAACAAACAAAGGGACCCA AAAATGTCTTGTATTAGAGTCACAATTGATCCGGAAAACAATTTAATTAGTATATGGAAT AATGGAAAAGGTATTCCTGTTGTTGAACACAAAGTTGAAAAGATGTATGTCCCAGCTCTC ATATTTGGACAGCTCCTAACTTCTAGTAACTATGATGATGATGAAAAGAAAGTGACAGGT GGTCGAAATGGCTATGGAGCCAAATTGTGTAACATATTCAGTACCAAATTTACTGTGGAA ACAGCCAGTAGAGAATACAAGAAAATGTTCAAACAGACATGGATGGATAATATGGGAAGA GCTGGTGAGATGGAACTCAAGCCCTTCAATGGAGAAGATTATACATGTATCACCTTTCAG CCTGATTTGTCTAAGTTTAAAATGCAAAGCCTGGACAAAGATATTGTTGCACTAATGGTC AGAAGAGCATATGATATTGCTGGATCCACCAAAGATGTCAAAGTCTTTCTTAATGGAAAT AAACTGCCAGTAAAAGGATTTCGTAGTTATGTGGACATGTATTTGAAGGACAAGTTGGAT GAAACTGGTAACTCCTTGAAAGTAATACATGAACAAGTAAACCACAGGTGGGAAGTGTGT TTAACTATGAGTGAAAAAGGCTTTCAGCAAATTAGCTTTGTCAACAGCATTGCTACATCC AAGGGTGGCAGACATGTTGATTATGTAGCTGATCAGATTGTGACTAAACTTGTTGATGTT GTGAAGAAGAAGAACAAGGGTGGTGTTGCAGTAAAAGCACATCAGGTGAAAAATCACATG TGGATTTTTGTAAATGCCTTAATTGAAAACCCAACCTTTGACTCTCAGACAAAAGAAAAC ATGACTTTACAACCCAAGAGCTTTGGATCAACATGCCAATTGAGTGAAAAATTTATCAAA GCTGCCATTGGCTGTGGTATTGTAGAAAGCATACTAAACTGGGTGAAGTTTAAGGCCCAA GTCCAGTTAAACAAGAAGTGTTCAGCTGTAAAACATAATAGAATCAAGGGAATTCCCAAA CTCGATGATGCCAATGATGCAGGGGGCCGAAACTCCACTGAGTGTACGCTTATCCTGACT GAGGGAGATTCAGCCAAAACTTTGGCTGTTTCAGGCCTTGGTGTGGTTGGGAGAGACAAA TATGGGGTTTTCCCTCTTAGAGGAAAAATACTCAATGTTCGAGAAGCTTCTCATAAGCAG ATCATGGAAAATGCTGAGATTAACAATATCATCAAGATTGTGGGTCTTCAGTACAAGAAA AACTATGAAGATGAAGATTCATTGAAGACGCTTCGTTATGGGAAGATAATGATTATGACA GATCAGGACCAAGATGGTTCCCACATCAAAGGCTTGCTGATTAATTTTATCCATCACAAC TGGCCCTCTCTTCTGCGACATCGTTTTCTGGAGGAATTTATCACTCCCATTGTAAAGGTA TCTAAAAACAAGCAAGAAATGGCATTTTACAGCCTTCCTGAATTTGAAGAGTGGAAGAGT TCTACTCCAAATCATAAAAAATGGAAAGTCAAATATTACAAAGGTTTGGGCACCAGCACA TCAAAGGAAGCTAAAGAATACTTTGCAGATATGAAAAGACATCGTATCCAGTTCAAATAT TCTGGTCCTGAAGATGATGCTGCTATCAGCCTGGCCTTTAGCAAAAAACAGATAGATGAT CGAAAGGAATGGTTAACTAATTTCATGGAGGATAGAAGACAACGAAAGTTACTTGGGCTT CCTGAGGATTACTTGTATGGACAAACTACCACATATCTGACATATAATGACTTCATCAAC AAGGAACTTATCTTGTTCTCAAATTCTGATAACGAGAGATCTATCCCTTCTATGGTGGAT GGTTTGAAACCAGGTCAGAGAAAGGTTTTGTTTACTTGCTTCAAACGGAATGACAAGCGA GAAGTAAAGGTTGCCCAATTAGCTGGATCAGTGGCTGAAATGTCTTCTTATCATCATGGT GAGATGTCACTAATGATGACCATTATCAATTTGGCTCAGAATTTTGTGGGTAGCAATAAT CTAAACCTCTTGCAGCCCATTGGTCAGTTTGGTACCAGGCTACATGGTGGCAAGGATTCT GCTAGTCCACGATACATCTTTACAATGCTCAGCTCTTTGGCTCGATTGTTATTTCCACCA AAAGATGATCACACGTTGAAGTTTTTATATGATGACAACCAGCGTGTTGAGCCTGAATGG TACATTCCTATTATTCCCATGGTGCTGATAAATGGTGCTGAAGGAATCGGTACTGGGTGG TCCTGCAAAATCCCCAACTTTGATGTGCGTGAAATTGTAAATAACATCAGGCGTTTGATG GATGGAGAAGAACCTTTGCCAATGCTTCCAAGTTACAAGAACTTCAAGGGTACTATTGAA GAACTGGCTCCAAATCAATATGTGATTAGTGGTGAAGTAGCTATTCTTAATTCTACAACC ATTGAAATCTCAGAGCTTCCCGTCAGAACATGGACCCAGACATACAAAGAACAAGTTCTA GAACCCATGTTGAATGGCACCGAGAAGACACCTCCTCTCATAACAGACTATAGGGAATAC CATACAGATACCACTGTGAAATTTGTTGTGAAGATGACTGAAGAAAAACTGGCAGAGGCA GAGAGAGTTGGACTACACAAAGTCTTCAAACTCCAAACTAGTCTCACATGCAACTCTATG GTGCTTTTTGACCACGTAGGCTGTTTAAAGAAATATGACACGGTGTTGGATATTCTAAGA GACTTTTTTGAACTCAGACTTAAATATTATGGATTAAGAAAAGAATGGCTCCTAGGAATG CTTGGTGCTGAATCTGCTAAACTGAATAATCAGGCTCGCTTTATCTTAGAGAAAATAGAT GGCAAAATAATCATTGAAAATAAGCCTAAGAAAGAATTAATTAAAGTTCTGATTCAGAGG GGATATGATTCGGATCCTGTGAAGGCCTGGAAAGAAGCCCAGCAAAAGGTTCCAGATGAA GAAGAAAATGAAGAGAGTGACAACGAAAAGGAAACTGAAAAGAGTGACTCCGTAACAGAT TCTGGACCAACCTTCAACTATCTTCTTGATATGCCCCTTTGGTATTTAACCAAGGAAAAG AAAGATGAACTCTGCAGGCTAAGAAATGAAAAAGAACAAGAGCTGGACACATTAAAAAGA AAGAGTCCATCAGATTTGTGGAAAGAAGACTTGGCTACATTTATTGAAGAATTGGAGGCT GTTGAAGCCAAGGAAAAACAAGATGAACAAGTCGGACTTCCTGGGAAAGGGGGGAAGGCC AAGGGGAAAAAAACACAAATGGCTGAAGTTTTGCCTTCTCCGCGTGGTCAAAGAGTCATT CCACGAATAACCATAGAAATGAAAGCAGAGGCAGAAAAGAAAAATAAAAAGAAAATTAAG AATGAAAATACTGAAGGAAGCCCTCAAGAAGATGGTGTGGAACTAGAAGGCCTAAAACAA AGATTAGAAAAGAAACAGAAAAGAGAACCAGGTACAAAGACAAAGAAACAAACTACATTG GCATTTAAGCCAATCAAAAAAGGAAAGAAGAGAAATCCCTGGTCTGATTCAGAATCAGAT AGGAGCAGTGACGAAAGTAATTTTGATGTCCCTCCACGAGAAACAGAGCCACGGAGAGCA GCAACAAAAACAAAATTCACAATGGATTTGGATTCAGATGAAGATTTCTCAGATTTTGAT GAAAAAACTGATGATGAAGATTTTGTCCCATCAGATGCTAGTCCACCTAAGACCAAAACT TCCCCAAAACTTAGTAACAAAGAACTGAAACCACAGAAAAGTGTCGTGTCAGACCTTGAA GCTGATGATGTTAAGGGCAGTGTACCACTGTCTTCAAGCCCTCCTGCTACACATTTCCCA GATGAAACTGAAATTACAAACCCAGTTCCTAAAAAGAATGTGACAGTGAAGAAGACAGCA GCAAAAAGTCAGTCTTCCACCTCCACTACCGGTGCCAAAAAAAGGGCTGCCCCAAAAGGA ACTAAAAGGGATCCAGCTTTGAATTCTGGTGTCTCTCAAAAGCCTGATCCTGCCAAAACC AAGAATCGCCGCAAAAGGAAGCCATCCACTTCTGATGATTCTGACTCTAATTTTGAGAAA ATTGTTTCGAAAGCAGTCACAAGCAAGAAATCCAAGGGGGAGAGTGATGACTTCCATATG GACTTTGACTCAGCTGTGGCTCCTCGGGCAAAATCTGTACGGGCAAAGAAACCTATAAAG TACCTGGAAGAGTCAGATGAAGATGATCTGTTTTAA
pfams:PF00521DNA_topoisoIVPF02518HATPase_cPF00204DNA_gyraseBPF08070DTHCTPF01751ToprimPF16898TOPRIM_C
go-classifiers:componentcondensed chromosomecomponentcytoplasmcomponentDNA topoisomerase complex (ATP-hydrolyzing)componentnucleoluscomponentnucleoplasmcomponentnucleuscomponentprotein complexfunctionATP bindingfunctionchromatin bindingfunctionDNA bindingfunctionDNA binding, bendingfunctionDNA topoisomerase type II (ATP-hydrolyzing) activityfunctionDNA-dependent ATPase activityfunctiondrug bindingfunctionenzyme bindingfunctionhistone deacetylase bindingfunctionmagnesium ion bindingfunctionpoly(A) RNA bindingfunctionprotein C-terminus bindingfunctionprotein heterodimerization activityfunctionprotein homodimerization activityfunctionprotein kinase C bindingfunctionubiquitin bindingprocessapoptotic chromosome condensationprocesscellular response to DNA damage stimulusprocesschromosome segregationprocessDNA ligationprocessDNA topological changeprocessDNA unwinding involved in DNA replicationprocessembryonic cleavageprocesshematopoietic progenitor cell differentiationprocessmitotic cell cycleprocessmitotic DNA integrity checkpointprocessmitotic recombinationprocesspositive regulation of apoptotic processprocesspositive regulation of single stranded viral RNA replication via double stranded DNA intermediateprocesspositive regulation of transcription from RNA polymerase II promoterprocesspositive regulation of viral genome replicationprocessregulation of circadian rhythmprocessresolution of meiotic recombination intermediatesprocessrhythmic processprocesssister chromatid segregation

酶

BE0002433Cytochrome P450 1A2HumansinhibitorA3686319590965Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E: Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J. 2009 Sep;11(3):481-94. doi: 10.1208/s12248-009-9127-y. Epub 2009 Jul 10.noCytochrome P450 1A2Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.CYP1A215q24Endoplasmic reticulum membrane9.4358293.7615HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2596GenAtlasCYP1A2GenBank Gene DatabaseZ00036Guide to Pharmacology1319UniProtKBP05177UniProt AccessionCP1A2_HUMAN1.14.14.1Cholesterol 25-hydroxylaseCYPIA2Cytochrome P(3)450Cytochrome P450 4Cytochrome P450-P3>lcl|BSEQ0004778|Cytochrome P450 1A2 MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN>lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2) ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGAPF00067p450componentendoplasmic reticulum membranecomponentintracellular membrane-bounded organellefunctionaromatase activityfunctioncaffeine oxidase activityfunctiondemethylase activityfunctionelectron carrier activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenprocessalkaloid metabolic processprocessarachidonic acid metabolic processprocesscellular respirationprocesscellular response to cadmium ionprocessdibenzo-p-dioxin metabolic processprocessdrug catabolic processprocessdrug metabolic processprocessepoxygenase P450 pathwayprocessexogenous drug catabolic processprocessheterocycle metabolic processprocesshydrogen peroxide biosynthetic processprocesslung developmentprocessmethylationprocessmonocarboxylic acid metabolic processprocessmonoterpenoid metabolic processprocessomega-hydroxylase P450 pathwayprocessoxidation-reduction processprocessoxidative deethylationprocessoxidative demethylationprocessporphyrin-containing compound metabolic processprocesspost-embryonic developmentprocessregulation of gene expressionprocessresponse to estradiolprocessresponse to immobilization stressprocessresponse to lipopolysaccharideprocesssmall molecule metabolic processprocesssteroid catabolic processprocesstoxin biosynthetic processprocessxenobiotic metabolic processmoderate

载体

运输工具

药物反应

效应

不良反应